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ABSTRACT

Shows, Hannah Willow. Ph.D., Biomedical Sciences Ph.D. Program, Wright State
University, 2021. Augmenting structure/function relationship analysis with deep learning
for the classification of psychoactive drug activity at Class A G protein-coupled
receptors.

G protein-coupled receptors (GPCRs) initiate intracellular signaling pathways via
interaction with external stimuli. [1-5] Despite sharing similar structure and cellular
mechanism, GPCRs participate in a uniquely broad range of physiological functions. [6]
Due to the size and functional diversity of the GPCR family, these receptors are a major
focus for pharmacological applications. [1,7] Current state-of-the-art pharmacology and
toxicology research strategies rely on computational methods to efficiently design highly
selective, low toxicity compounds. [9], [10] GPCR-targeting therapeutics are associated
with low selectivity resulting in increased risk of adverse effects and toxicity.
Psychoactive drugs that are active at Class A GPCRs used in the treatment of
schizophrenia and other psychiatric disorders display promiscuous binding behavior
linked to chronic toxicity and high-risk adverse effects. [16-18]
We hypothesized that using a combination of physiochemical feature engineering
with a feedforward neural network, predictive models can be trained for these specific
GPCR subgroups that are more efficient and accurate than current state-of-the-art
methods.. We combined normal mode analysis with deep learning to create a novel
framework for the prediction of Class A GPCR/psychoactive drug interaction activities.
iii

Our deep learning classifier results in high classification accuracy (5-HT F1-score = 0.78;
DRD F1-score = 0.93) and achieves a 45% reduction in model training time when
structure-based feature selection is applied via guidance from an anisotropic network
model (ANM). Additionally, we demonstrate the interpretability and application potential
of our framework via evaluation of highly clinically relevant Class A
GPCR/psychoactive drug interactions guided by our ANM results and deep learning
predictions. Our model offers an increased range of applicability as compared to other
methods due to accessible data compatibility requirements and low model complexity.
While this model can be applied to a multitude of clinical applications, we have presented
strong evidence for the impact of machine learning in the development of novel
psychiatric therapeutics with improved safety and tolerability.

iv

Table of Contents
1. Introduction ......................................................................................................................1
1.1 Significance and Impact .............................................................................................1
1.2 Specific Aims .............................................................................................................3
2. Literature Review.............................................................................................................6
2.1 G protein-coupled receptors .......................................................................................6
2.2 Psychiatric disorder epidemiology and pharmacology ............................................10
2.3 Pharmacodynamics and SBDD ................................................................................14
2.4 Computational tools .................................................................................................15
2.4.1 Modeling and simulation ..............................................................................15
2.4.2 Machine learning ..........................................................................................17
2.4.3 Performance metrics .....................................................................................19
2.4.4 Hyperparameter tuning .................................................................................26
2.4.5 Feature selection methods .............................................................................27
2.4.6 Machine learning algorithms ........................................................................31
2.4.6.1 Regression ......................................................................................31
2.4.6.2 Decision tree-based models ...........................................................37

v

2.4.6.3 Support vector machines ................................................................41
2.4.7 Neural Networks .......................................................................................44
2.5 Bioinformatics methods ...........................................................................................49
2.5.1 Molecular dynamics simulation ....................................................................49
2.5.2 Machine learning models for bioinformatics ................................................51
2.5.3 Anisotropic Network Model .........................................................................53
2.5.4 Protein structural comparison methods .........................................................56
3. Methodology ..................................................................................................................60
3.1 Literature Search and Model Selection ....................................................................60
3.2 Data collection and cleaning ....................................................................................62
3.3 Synthetic datapoint generation .................................................................................68
3.4 Anisotropic network model ......................................................................................69
3.5 Structural analysis using molecular modeling and simulation .................................72
3.6 Logistic regression model parameters ......................................................................75
3.7 Decision tree-based model parameters .....................................................................76
3.8 Support vector machine model parameters ..............................................................77
3.9 AdaBoost model parameters ....................................................................................78
3.10 Performance metrics and cross validation methods ...............................................79
3.11 Deep neural network model parameters and architecture ......................................80
3.3 Synthetic datapoint generation .................................................................................77
vi

4. Results and Discussion ..................................................................................................82
4.1 Specific Aim 1. To test the performance of current machine learning algorithms for
the classification of protein binding behavior and determine the extent to which these
architectures can be applied to the classification of Class A GPCR-drug interactions ..82
4.1.1 Current state-of-the-art method performance against a DUD-E benchmark
dataset .............................................................................................................................78
4.1.2 Current state-of-the-art method performance against a GPCR Subgroup A17
test set .............................................................................................................................85
4.1.3 Discussion of current published models and potential applicability to
Subgroup A17 proteins ..........................................................................................87
4.2 Specific Aim 2. To assess the degree with which model performance of a Class A
GPCR subgroup classifier can be maintained as we reduce time complexity via
structure-based feature selection ...................................................................................92
4.2.1 Multiple structural alignment of Class A GPCRs .........................................92
4.2.2 Anisotropic network model analysis of Class A GPCR proteins .................95
4.2.3 Comparative structural analyses of Class A GPCR binding behavior and
discussion of potential evidence provided by ANM data ......................................97
4.2.4 Influence of structure-based feature selection as determined by ANM on the
accuracy and associated time-cost of Class A subgroup classifiers ....................101

vii

4.3 Specific Aim 3. To implement a novel deep neural network classifier for the binary
prediction of drug-binding behavior for a dataset of (a) serotonin and (b) dopamine
Class A GPCRs. ..........................................................................................................105
4.3.1 Implementation of structure-based feature selection methods for deep neural
network classifiers ...............................................................................................105
4.3.2 Deep learning classification of 5-HT receptor drug-target activities..........108
4.3.3 Deep learning classification of DRD receptor drug-target activities ..........110
4.3.4 Discussion of machine learning classifier performance for drug-target
interaction activities of 5-HT and DRD receptors ...............................................112
4.3.5 DRD drug-target interaction selectivity prediction for specific clinical
applications ..........................................................................................................110
5. Conclusion and Future Work .......................................................................................121
References ........................................................................................................................126
Appendix A. Receptor and Drug Features .......................................................................155
A.1. Receptor feature engineering from ANM output .........................................155
A.2. Drug feature encoding ..................................................................................156
Appendix B. Code Source and Examples ........................................................................158
B.1. Dataset generation and cleaning ...................................................................158
B.2. Data loaders ..................................................................................................159
B.3. Deep learning classifier ................................................................................160
viii

B.4. Other machine learning models....................................................................161
B.5. Anisotropic network model ..........................................................................162
B.6. Protein structure modeling and analysis.......................................................163

ix

List of Figures
Figure 1. Schematic of a ligand-bound Class A GPCR embedded in the plasma
membrane. ............................................................................................................................6
Figure 2. GPCR activation cycle. ........................................................................................7
Figure 3. Classification of the GPCR superfamily. ............................................................8
Figure 4. GPCR binding sites for extracellular ligands and intracellular G proteins .........9
Figure 5. Molecular modeling and dynamics simulations strategies for in silico structural
analysis. .............................................................................................................................15
Figure 6. Feature extraction process from a protein structure. .........................................17
Figure 7. Linear regression model. ...................................................................................32
Figure 8. Logistic regression model. .................................................................................35
Figure 9. Decision tree and random forest models ...........................................................37
Figure 10. AdaBoost model. .............................................................................................40
Figure 11. Support vector machine ...................................................................................41
Figure 12. Neural network structure .................................................................................45
Figure 13. Convolutional neural network architecture .....................................................48
Figure 14. Representation of the molecular model of water used in the TIP4P-EW
solvation model. ................................................................................................................73
x

Figure 15. Architecture of feedforward, fully-connected deep neural network used for
drug-target interaction prediction of Subgroup 17 receptors ............................................81
Figure 16. Protein-ligand interaction classifiers perform significantly worse than reported
accuracy metrics on a test set containing Subgroup A17 GPCRs. ...................................84
Figure 17. Multiple structural alignment of Class A GPCR proteins ..............................93
Figure 18. Multiple structural alignment of serotonin receptors 5-HT1A (PDB 7E2X), 5HT1B, (PDB 5V54) 5-HT2A (PDB 6A94), and 5-HT2C (PDB 6DS0). ..........................93
Figure 19. Multiple structural alignment of the D2 (PDB 6VMS)/D3 (PDB 6CMU)/D4
(PDB 5WIV) receptors focused on the binding site. ........................................................94
Figure 20. Visualization of 5-HT1A Anisotropic Network Model, normal mode 1 out of
20 normal modes generated. .............................................................................................96
Figure 21. Results from the rhodopsin ANM yield a different residue set than other
structural analysis methods. ..............................................................................................98
Figure 22. Serotonin receptor atomic fluctuation data identifies important residues
outside of binding pocket as evidenced by analysis of the 5-HT1A/LSD complex. ........99
Figure 23. Regions identified as important by ANM analysis highly influence haloperidol
binding in psychoactive drug receptors.

......................................................................100

Figure 24. Synthetic data generation to correct class imbalance within the Class A GPCR
dataset via SMOTE. ........................................................................................................101
Figure 25. Reducing feature set by 85% via structural-based variance threshold does not
significantly reduce cross-validated F1-score based-accuracy of classifiers including
xi

support vector machine, K-nearest neighbors, bagging trees, random forest and extra
trees. (k=10)
..........................................................................................................................................102
Figure 26. Reducing feature set by 85% via structural-based variance threshold
significantly reduces training time of classifiers including support vector machine, Knearest neighbors, bagging trees, random forest and extra trees. (k=10) ........................103
Figure 27. Deep neural network classifier prediction of serotonin receptor activity
accuracy was not significantly reduced when the receptor feature set is reduced by 85%
as determined by a 10-fold cross validated F1-score or ROC AUC score.
..........................................................................................................................................107
Figure 28. Training time for a deep neural network classifier of serotonin receptor
activity was significantly reduced by 45% when the receptor feature set is reduced by
85%.
..........................................................................................................................................107
Figure 29. Deep neural network classifier substantially outperformed other classifiers (F1
= 0.78, AUC = 0.768) for prediction of serotonin receptor binding behavior, including
logistic regression, random forest, support vector machine, and Adaboost as measured by
cross-validated F1-score and cross-validated ROC AUC. (k = 10)
..........................................................................................................................................109
Figure 30. Deep neural network classifier substantially outperformed other classifiers (F1
= 0.93, AUC = 0.941) for prediction of dopamine receptor binding behavior, including
xii

logistic regression, random forest, support vector machine, and Adaboost as measured by
cross-validated F1-score and cross-validated ROC AUC. (k = 10)
..........................................................................................................................................111
Figure 31. Accuracy of the deep neural network classifier on a test set of selective DRD
drug-target interactions. ...................................................................................................118
Figure 32. Accuracy of the deep neural network classifier on a test set of drug-target
interactions selective for the D2 or D4 receptor. ............................................................120

xiii

List of Tables
Table 1. Common activation functions for neural networks, their first derivatives, and
ranges. ................................................................................................................................46
Table 2. Comparison of selected protein-ligand interaction deep learning models ...........61
Table 3. TIP4P model parameters ......................................................................................72
Table 4. TIP4P-Ew model parameters ...............................................................................73
Table 5. Logistic regression model hyperparameters ........................................................75
Table 6. Decision-tree based model hyperparameters .......................................................76
Table 7. Support vector machine model hyperparameters.................................................77
Table A1.1 Format of data features for protein receptors ................................................155
Table A2.1 Molecular descriptors selected from the RDKit package to be used as features
in machine learning prediction.........................................................................................156

xiv

List of Acronyms
5-HT
AdaBoost
ADHD

5-hydroxytryptamine (also
referred to as serotonin)
Adaptive boosting

ANM

Attention-deficit
hyperactivity disorder
Anisotropic network model

ANOVA

Analysis of variance

AUC

Area under the curve

AWS

Amazon Web Services

BLOSUM62 Blocks Substitution Matrix,
62% assumed conservation
ChEMBL
Chemogenomic European
Molecular Biology
Laboratory Database
CNN
Convolutional neural network
CoV

Coronavirus

DNA

Deoxyribonucleic acid

DRD

ECL

Dopamine receptor D (as in,
dopamine receptor D1, D2,
etc)
Define secondary structure of
proteins
Database of Useful DecoysEnhanced
Extracellular loop

ELU

Exponential Linear Unit

DSSP
DUD-E

xv

ET

Extra trees

FDA
FN

Food and Drug
Administration
False negative

FP

False positive

GABA

Gamma-aminobutyric acid

GDP

Guanosine diphosphate

GI

Gastrointestinal

GNM

Gaussian network model

GPCR

G protein-coupled receptor

GPCRdb
GPU

G Protein-Coupled Receptor
Database
Graphics processing unit

GTP

Guanosine triphosphate

HIV-1
ICL

Human immunodeficiency
virus 1
Intracellular loop

Kd

Dissociation constant

Ki

Inhibition constant

KNN

K-nearest neighbors

LBFGS
LDA

Limited-memory BroydenFletcher-Goldfarb-Shanno
Linear discriminant analysis

LLE

Locally linear embedding

LSD

Lysergic acid diethylamide
xvi

MAE

Mean absolute error

MDD

Major depressive disorder

MDPV

Methylenedioxypyrovalerone

MDS

Multi-dimensional scaling

MSE

Mean squared error

NCBI

National Center for
Biotechnology Information
Nanomolar

nM
O-PLS

PCA

Orthogonal partial least
squares (also referred to as
orthogonal projection to
latent structures)
Principal component analysis

PDB

Protein Data Bank

PDE

Phosphodiesterase

PDSP
PLS

Psychoactive Drug Screening
Program
Partial least squares

PPP

Pyrrolidinopropiophenone

PRAUC

Precision-recall area under
the curve
Pyrrolidinopentiothiophenone

PVT
QSAR
RBF

Quantitative structureactivity relationship
Radial basis function

ReLU

Rectified Linear Unit

RF

Random forest

xvii

RFE

Recursive feature elimination

RMSD

Root-mean-square deviation

ROC
SAG

Receiver operating
characteristics
Stochastic average gradient

SBDD

Structure-based drug design

SMILES

Simplified molecular-input
line-entry system
Synthetic minority
oversampling technique
Structured query language

SMOTE
SQL
SSRI
SVM

Selective serotonin reuptake
inhibitors
Support vector machine

TN

True negative

TP

True positive

t-SNE

t-distributed stochastic
embedding
United States dollar

USD

xviii

Acknowledgments
I am incredibly grateful to my advisor, Dr. Michael Raymer, for the amount of
support and guidance he has provided to me over the course of my doctoral work. None
of this would be possible without his expertise, patience, and most importantly, his
enthusiasm and kindness. Thank you for always believing in me. I would like to
acknowledge and thank my committee members (Dr. David Cool, Dr. Jeffery Gearhart,
Dr. Courtney Sulentic, Dr. Michael Leffak, and Dr. Mill Miller) for all of their crucial
guidance and supervision. I would also like to acknowledge and thank Dr. Mill Miller,
Dr. David Ladle, and Karen Luchin with the BMS program for this opportunity. In
particular, I am highly indebted to Dr. Mill Miller as his advice, humor, and pointed
honesty were instrumental in many challenging moments.
Thank you to all of the role models and teachers throughout this journey – in
particular, Dr. Tara Smith, Dr. Brandon Davies, and Dr. Emily Cushing.
I owe so much to my family and friends for their love and support. Thank you for
always providing a listening ear, a shoulder to cry on, and food. To my incredible support
system of brilliant women, with special recognition to Dr. Xiu Huan Yap, Dr. Sara
Seibert, Dr. Devon Price, Dr. Dylan Cutler, Dr. Nikita Wagle, Brooke Kranzler, Christina
Dietz, Linda Haviv, Chandler McElrath, Melissa Ward, Erika Aguirre, Kimberly Fiock,
Coraline Holquist, Danielle Hausberger, Hollyann Seitz, Jennifer Barrow, and Evelyn
Kinne. I would also like to highlight Chris Waker and Clayton Allex-Buckner as both
colleagues and friends. Most importantly of all, to Zach Powell—there are no words to
accurately describe the depth of my gratitude. Thank you for everything.
xix

Dedication
This dissertation is dedicated to the memory of Lucas Marquardt.

xx

1. Introduction
1.1

Significance and Impact

G protein-coupled receptors (GPCRs) are a family of proteins that interact with
extracellular ligands to transduce intracellular signals via binding to a partner
heterotrimeric G protein. [1]–[5] There are approximately 800 known GPCRs in the
human genome with a diverse range of functions, including roles in neurological,
homeostatic, and endocrine pathways. [2], [6] As a result, the GPCR family is a major
research focus for clinical and pharmacological applications. [1], [7] Over 30% of FDAapproved compounds target GPCRs. [8] In recent years, structure-based drug design
(SBDD) methods have gained popularity due to their increased time- and cost-associated
efficiency and ability to produce target-specific, low toxicity compounds. [9], [10]
Numerous drugs produced by SBDD are currently available in market; of note, multiple
HIV-1 and anti-cancer agents were designed with the aid of computational tools. [11],
[12] SBDD methods include machine learning (e.g., regression, clustering, and deep
learning) and molecular modeling (e.g., ligand docking)
SBDD tools are ideal for the study of GPCR-targeting ligands. A high proportion of
drugs targeting GPCRs are at the upper limit of Lipinski’s rule of five in terms of
molecular weight and lipophilicity, which correlates to lower selectivity and increased
risk of toxicity. [13]–[15] In particular, psychoactive drugs that target Class A GPCRs
such as serotonin and dopamine receptors (e.g., antidepressants, antipsychotics, and
1

mood stabilizer agents) display high rates of chronic toxicity and cross-reactivity as a
result of low selectivity. [16]–[18] Existing methods for predicting drug-target activities
require a high volume of training data and time. We hypothesize that using a combination
of physiochemical feature engineering with a feedforward neural network, predictive
models can be trained for these specific GPCR subgroups that are more efficient and
accurate than current state-of-the-art methods.
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1.2

Specific Aims

Specific Aim 1. To test the performance of current machine learning algorithms
for the classification of protein binding behavior and determine the extent to which
these architectures can be applied to the classification of Class A GPCR-drug
interactions.
Objective: 1a. We will establish a baseline performance for modern classification
methods of protein-ligand binding behavior via replicating current models from the
recent literature [19]–[22] and optimizing their hyperparameters for the best performance
against standard benchmark protein interaction datasets. [23]–[27] 1b. Optimized models
will be tested for accuracy against the binary activity classification of an interaction
dataset between Class A GPCRs and their respective drug binding partners to establish an
additional baseline for the application potential of machine learning models to Class A
GPCR binding behavior.
Specific Aim 2. To assess the degree with which model performance of a Class
A GPCR subgroup classifier can be maintained as we reduce time complexity via
structure-based feature selection.
Objective: Current predictive models often use fully comprehensive structure and/or
sequence data in their feature sets risking the inclusion of irrelevant features. Irrelevant
additional features may decrease model accuracy and increase computation time. [28] We
hypothesize that by rationally decreasing our feature set by focusing on regions of the
3

structural landscape with the highest variation within a dataset, we will be able to reduce
data noise and model time performance. A combination of anisotropic network model
analysis and machine learning classifiers will be used to predict the subgroup of Class A
GPCR protein structures. We hypothesize that reducing our feature space will decrease
average training time of a model without a consequential decrease in classification
accuracy. If accuracy is maintained, the resulting decreased computation time of our
model will therefore be better suited to examine our data in finer detail and increase our
ability to extract a higher degree of learning from our model.
Specific Aim 3. To implement a novel deep neural network classifier for the
binary prediction of drug binding activity for a dataset of (a) serotonin and (b)
dopamine Class A GPCRs.
Objective: We will develop a deep learning model for the binary activity
(active/inactive) classification of Class A GPCR-small molecule interactions. This
network will be separately trained and optimized for two subgroups of the Class A
GPCRs respectively, the (3a) serotonin (5-HT) and (3b) dopamine (DRD) receptors.
These interactions are clinically relevant to the development of numerous psychoactive
compounds; of note, antipsychotic and antidepressant drugs. [8], [17], [27], [29], [30]
Overall Impact: We hypothesize that by implementing modern state-of-the-art
strategies to optimize parameters for these models, we will be able to improve upon
current drug-target interaction prediction accuracy while establishing a novel baseline
performance for a specific clinical application. As a result, an efficacious predictive tool
for the binding behavior of these receptor subtypes has considerable impact potential

4

from a translational perspective, as well as providing a technical innovation for the use of
deep learning in computational biochemistry.
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2. Literature Review
2.1

G protein-coupled receptors.

The G protein-coupled receptor (GPCR) superfamily of proteins interact with
extracellular ligands to influence intracellular G protein-mediated signaling behavior.
GPCRs are membrane-embedded proteins structurally characterized by their alpha helix
barrel structure. (Figure 1) [2], [31]

Figure 1. Schematic of a ligand-bound Class A GPCR embedded in the plasma membrane. Threedimensional structure of the human D2-receptor, (green) a GPCR belonging to the A17 subfamily, bound
to bromocriptine (purple) in the extracellular orthosteric binding site while embedded in the plasma
membrane. Adapted from PDB 6VMS and modeled in UCSF Chimera.

When activated by a ligand, the receptor binds to a partner heterotrimeric G protein
and promotes exchange of GTP for GDP, leading to a wide range of downstream
signaling effects. [1] The interaction between the GPCR and partner G protein relies on a
substantial conformational change of the GPCR resulting from interactions with the
6

extracellular ligand. Generally, the inactive GPCR conformation stabilizes interactions
with a GDP-bound G protein while active conformations promote exchange of GTP for
GDP from the G protein alpha subunit. Consequently, the GTP-bound alpha subunit
dissociates from the beta and gamma subunits (which also later dissociate) and the
dissociated subunits separately mediate downstream signaling activities. [32] This cycle
is represented in Figure 2.

Figure 2. GPCR activation cycle. Cycle demonstrating the exchange of GDP for GTP with a partner G protein upon ligand binding
to a GPCR.

Agonists, or activating ligands, stabilize the active conformation while inverse
agonists stabilize the inactive conformation. Antagonists do not affect the equilibrium of
the receptor but instead compete with agonists for the orthosteric binding site. However,
GPCRs are not simple on/off switches. There is a preexisting equilibrium between
inactive and active conformations, and the equilibrium can be shifted when agonists
promote GTP exchange activity above the basal level to favor an active conformation or
when inverse agonists lower activity below the basal level and thus favor an inactive
7

conformation. [5] Partial agonists may affect the activity equilibrium of the receptor at a
partial efficacy compared to a full or inverse agonist.
GPCRs are the largest family of membrane proteins and mediate a diverse range of
biological processes. GPCR activity is mediated by light, hormones, neurotransmitters,
odors, pheromones, and many other peptides and small ligands. [1] While GPCRs share
similar structure, they are grouped into Classes A-F (Figure 3) based on their ligand
binding behavior, with Class A (rhodopsin- and rhodopsin-like receptors) containing 85%
of all GPCRs. As a result, Class A is further divided into subgroups A1-A19. [3], [4],
[33] Approximately one-third of all FDA-approved drugs target GPCRs, predominately
focused on Class A receptors. [34]–[36] The global sales volume for GPCR-targeting
drugs was approximately 180 billion USD in 2018. [34]

Figure 3. Classification of the GPCR superfamily. Classes A-F grouping of the GPCR superfamily. Of note, Class A17 contains the
majority of serotonin and dopamine receptors along with the adrenergic, trace amine, and histamine H 2 receptors.

GPCRs possess seven transmembrane-spanning helices, as well as a varying number
of extracellular loops (ECL) and intracellular loops (ICL) which interact with
extracellular ligands and a G protein, respectively. (Figure 4) GPCR ECL contain
conserved cysteine residues that form structurally-important disulfide bonds. These ECL
8

are also typically glycosylated. The ECL2 region is often involved in the binding
mechanism within Class A, as well as key transmembrane domain residues (often, a
highly conserved tryptophan residue referred to as the toggle switch at position W6.48)
and residues within ICL2 and ICL3. [1], [5]

Figure 4. GPCR binding sites for extracellular ligands and intracellular G proteins. Twodimensional representation of a GPCR (green) bound to an extracellular ligand (purple) and an
intracellular heterotrimeric G protein (blue).

GPCRs are closely involved in behavior and mood regulation via binding ligands
such as serotonin, dopamine, GABA, histamine, glutamate, opioids and cannabinoids.
[27], [37]–[41] As a result, they are often studied in the context of behavioral medicine,
psychiatry, and substance use disorders. The relationship of certain GPCRs with
therapeutic and recreational use of psychoactive compounds has been well characterized.
[39], [42]–[46]

9

2.2

Psychiatric disorder epidemiology and pharmacology.

Therapeutics that target small molecule neurotransmitter (e.g., serotonin, dopamine,
norepinephrine) receptors and transporters are often used in the treatment of disorders
such as major depressive disorder, bipolar disorder, and schizophrenia. Major depressive
disorder (MDD) is characterized by depressed mood, loss of pleasure, weight fluctuation,
insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, low self-esteem,
and general executive dysfunction. [47] More than 262 million people have MDD,
making the disorder the leading cause of disability worldwide. [48] The risk of suicide
within MDD-affected individuals is approximately 20 times higher than that of the
general population. Additionally, approximately 17% of individuals with MDD have a
co-morbid substance use disorder. [49], [50] The literature predominately attributes the
pathophysiology of MDD to hypoactivity of monoamine neurotransmitters such as
serotonin, although numerous other pathways have been implicated (e.g., cytokine
function and the cortico-limbic system). [27], [51], [52]
Selective serotonin reuptake inhibitors (SSRIs) are used to treat depressive
symptoms in MDD and other behavioral health disorders via increasing the extracellular
concentration of serotonin in the synaptic cleft by limiting its reuptake into the
presynaptic cell. [53] While SSRIs are designed to target serotonin transporters, they also
often have affinity for norepinephrine and dopamine transporters as well as GPCRs such
as the serotonin, opiate, histamine, acetylcholine, and norepinephrine receptors. [42],
10

[45], [53] While newer generations of antidepressant medication exhibit increased
selectivity, the SSRI class of drugs exhibit side effects such as sexual dysfunction,
increased risk of bone fractures, suicide risk, akathisia, weight gain, QT prolongation and
interactions with anticoagulants that result in a risk of increased GI bleeding. [42], [54]–
[59] Examples of common SSRI drugs include citalopram, escitalopram, fluoxetine,
fluvoxamine, paroxetine, and sertraline.
Bipolar disorders are characterized by recurrent, cyclic episodes of elevated mood
and depression which cause characteristic cognitive, physical, and behavioral symptoms.
[60] Hallmark symptoms of bipolar disorder include alternating states of mania and
depression, impaired executive function, and psychosis. [61]–[63] Over 30% of
individuals with bipolar also struggle with a substance use disorder and are twice as
likely to experience physical or sexual abuse compared to neurotypical individuals. [64],
[65] Greater than 6% of bipolar individuals die via suicide, highlighting the necessity for
effective symptom management. [66], [67] Lifelong psychiatric treatment is often
necessary for bipolar patients; however, large meta-analysis studies assessing adherence
to medication regimen found that only 54% of bipolar patients were fully adherent to
maintenance drugs. [41], [68], [69] Bipolar disorder is often treated with antipsychotic or
benzodiazepine medications with known side effects such as narcolepsy or insomnia,
weight gain or loss, tremors, akathisia, parkinsonism, and dystonia. [16], [17], [43], [69]
Schizophrenia and schizoaffective disorders are characterized by hallucinations,
delusions, and disordered thinking that impairs daily functioning. [40] Many of the
cognitive defects present in bipolar disorder are also symptoms of schizophrenia, as well
as overlapping psychotic symptoms (although these symptoms are typically more
11

prominent in schizophrenia). [70], [71] Approximately 50% of schizophrenic individuals
have mental and/or behavioral health comorbidities; of note, the rate of substance use
disorders is twice as high in the schizophrenic population as compared to the general
population. [44], [72] An estimated 5% of people with schizophrenia die via suicide. [66]
Schizophrenic patients are often prescribed similar medications to those being treated for
bipolar disorder and experience comparable prescription noncompliance rates as bipolar
patients. [40]
There are 114 known specific loci in the human genome that contribute to the risk of
both schizophrenia and bipolar disorder, compared to only four known regions that
differentiate the biology of the two disorders. [73] While the molecular basis of these
diseases is not fully understood, the two disorders both demonstrate defects with
dopamine signaling pathways. Antipsychotic medications are a subclass of neuroleptic
psychoactive compounds used to treat a range of psychiatric disorders primarily known
for their efficacy in the treatment of schizophrenia and bipolar disorder. Antipsychotics
are grouped into the typical and atypical classes based on chemical similarity. Typical
antipsychotics, also known as first-generation antipsychotics, include the
butyrophenones, diphenylbutylpiperidines, phenothiazines and thioxanthenes. Atypical
antipsychotics, or second-generation antipsychotics, include the benzamides,
benzisoxazoles, phenylpiperazines, and tricyclics. Antipsychotic medications often
function as dopamine receptor antagonists (in particular, DRD2) and serotonin receptor
antagonists (in particular, 5-HT2A and 5-HT2C) but do not have a selective mechanism.
[16], [74], [75] In addition to binding a wide range of dopamine and serotonin receptors,
antipsychotics also can interact with multiple other GPCRs including the cholinergic and
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histaminergic receptors. [17], [30], [76], [77] The number of target receptors a drug
interacts with is directly correlated with its adverse effects. [78], [79] Side effects are
often reported as a factor in poor prescription adherence in both bipolar and
schizophrenia patients due to negative impact on quality of life. [17], [53], [68]
Antipsychotics have documented side effects including sexual dysfunction, metabolic
syndrome, extreme weight fluctuation, gynecomastia, movement disorders, renal toxicity
and shrinkage of brain tissue volume leading to permanent disability. [16]–[18], [80]
Collectively, this clinical and biochemical evidence demonstrates a need for a
thorough investigation into the pharmacodynamics of GPCR interactions with
psychoactive drugs, allowing for the development of future candidates that are capable of
highly selective and efficacious receptor antagonism.
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2.3

Pharmacodynamics and SBDD.

The pharmacodynamics of a drug-target interaction include the study of how a drug
affects an organism on a molecular and physiological level. Studying the chemical
interactions that result in receptor binding on a molecular level often help explain the
dose response, toxicology, and physiologic changes that result from a drug interaction on
the organismal level. [81] As a result, structural biochemistry analysis of protein-ligand
interactions yields useful information for studying the behavior of therapeutic
compounds. [7], [82], [83] SBDD has gained popularity over the last thirty years due to
resulting production of selective, lower toxicity compounds associated with decreased
time- and financial- cost. Several FDA-approved drugs were produced by SBDD
methods, including successful HIV-1 inhibitors and chemotherapy agents developed
using computational tools. [11], [84] SBDD methodology may include computational
techniques such as machine learning (e.g., regression, clustering, and deep learning
techniques) and molecular modeling (e.g., ligand docking, molecular dynamics
trajectories).
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2.4

Computational tools.

2.4.1

Modeling and simulation

In early stages of the integration of in silico techniques into biochemical research,
simple statistics-based simulation models (such as Monte Carlo sampling) were used to
represent atomic positions within a molecule over a time course. [85]–[89] These
simulations evolved further into complex molecular dynamics trajectories capable of
predicting and estimating the thermodynamics and kinetics of a molecule’s
intermolecular interactions with binding partners or solvent, as well as its intramolecular
interactions. [82], [83], [90] Advances in molecular modeling technology have been
crucial for the development of modern structure determination techniques and ligand
docking models have become a mainstay of pharmacological research. (Figure 5) [91],
[92]

Figure 5. Molecular modeling and dynamics simulations strategies for in silico structural analysis. A Simulated model of a
protein structure (yellow) bound to multiple ligands (red) while solvated in NaCl solution. Generated using UCSF Chimera. B
Cartoon representation of ligand docking in which a protein receptor model (green) is simulated in solvent (not shown) with a
ligand (purple; not to scale) to generate a predicted bound structure.
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While modeling and simulation-based techniques are powerful, they possess a
complex feature space and as a result, are computationally expensive. [93], [94] Output
quality is often sacrificed in the form of short timescales and oversimplified
representations of the physiochemical parameters to minimize the feature space, allowing
for calculations to be completed in a reasonable timeframe. [95]–[97] Within recent
years, machine learning tools capable of handling “big data” problems have been applied
to computational biochemistry research to address the large feature space and amount of
output data produced when studying molecular interactions. [20], [22], [98]–[100]
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2.4.2

Machine learning

Machine learning models are named for their ability to learn from data. Machine
learning is defined with respect to a given task as an algorithm in which performance
improves with experience. [101] Machine learning models are shown examples of data
observations to learn from where our data is described by a collection of features. Each
data observation is typically represented as a vector 𝒙 where each entry 𝑥𝑖 of the vector is
a unique feature. (Figure 6) Common machine learning tasks include classification,
regression, anomaly detection, and density estimation. [102]

Figure 6. Feature extraction process from a protein structure. As an example, consider a protein structure as a single raw data
observation. Descriptors are extracted from this observation, such as polarity and charge. These descriptor values can be stored as
feature values in a given vector index 𝑥𝑖 . This input vector of features 𝑥 can be mapped to an output value or vector of values 𝑦
such as the binary output ‘1’ shown here, such as a classifier predicting a drug interaction being ‘active’ or ‘inactive’ for the given
receptor, which can be coded as {1} or {0}.

When machine learning models are given example data to learn from, we refer to
this process as training and the data as the training dataset. The model is categorized as
17

supervised or unsupervised based on the presence of labels in our data. Unsupervised
models observe examples of data in the form of a random vector 𝒙 and attempt to
estimate the probability distribution 𝑝(𝒙). Supervised models observe examples of data
in the form of a random vector 𝒙 and an associated vector 𝒚 (label or output data) and
learn to predict 𝒚 from 𝒙 by estimating 𝑝(𝒚 | 𝒙). Unsupervised models train on an
unlabeled dataset containing many features and identify useful structural patterns in the
data based on these features. Supervised models train on labeled datasets where the
relationship between the input and output can be estimated. [102]
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2.4.3

Performance Metrics

We evaluate performance measures of our model on a test set of data. Our test
dataset contains example data that the model has not previously seen. Performance is
typically assessed via measures of accuracy, precision, and error. One must choose the
most appropriately informative performance measure for a given specific task (e.g.,
measuring the performance of a classifier versus a regression model). Common measures
of accuracy and error for a classifier model, such as the models presented in this research,
include mean absolute error (MAE), mean squared error (MSE), classification accuracy,
confusion matrices, F1 score, and other measures of precision and recall such as the
receiver operating characteristics (ROC), area under curve (AUC), and area under
precision-recall curve (PRAUC). [103]–[105]
MAE refers to the average difference between the true and predicted values for a
dataset. MAE is a good measure of the magnitude of difference between predicted and
true output but does not indicate the direction of the error (e.g., overpredicting one class
over the others). [105] MAE is represented by:
𝑛

1
𝑀𝐴𝐸 = ∑|𝑦𝑗 − 𝑦̂𝑗 |
𝑛

(1)

𝑗=1

MSE is very similar to MAE, mathematically differing only by taking the average of
the squared difference between the predicted and true values for a dataset. [106] In
19

practice, this allows the gradient to be computed more easily. By taking the square of the
difference there is a much greater penalty for larger errors. [105] MSE is defined as:
𝑛

1
2
𝑀𝑆𝐸 = ∑(𝑦𝑗 − 𝑦̂𝑗 )
𝑛

(2)

𝑗=1

Classification accuracy is a much simpler measure of accuracy; however, it is not as
descriptive when there is an uneven distribution of samples between classes.

𝐶𝑙𝑎𝑠𝑠𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =

𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑜𝑛𝑠
𝑇𝑜𝑡𝑎𝑙 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑜𝑛𝑠 𝑚𝑎𝑑𝑒

(3)

A confusion matrix describes the complete performance of a given classifier with the
counts of true positives, false positives, true negatives, and false negatives. These counts
form the basis for other performance measures such as precision, recall, F1-scoring and
AUC/ROC curves. [104], [105] When testing a model with 𝑛 samples, the confusion
matrix resembles:
n = TN + FP +

Predicted No

Predicted Yes

Total number of

Total number of

FN+ TP
No

true negatives (TN)
Yes

Total number of
false negatives (FN)

false positives (FP)
Total number of
true positives (TP)

Precision and recall are the foundation of many other metrics, defined as:
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𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 =

𝑅𝑒𝑐𝑎𝑙𝑙 =

𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 + 𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠

𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 + 𝐹𝑎𝑙𝑠𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠

(4)

(5)

Precision represents the fraction of relevant instances to all retrieved instances, while
recall represents the fraction of retrieved instances to all relevant instances. Precision
measures the ability of a model to return only relevant instances while recall (also
referred to as sensitivity) measures the ability of a model to identify all relevant
instances. In some cases, we may optimize precision or recall at the expense of the other
or we may attempt to find an optimal balance between the two metrics. The F1 score
[105] is the harmonic mean of precision and recall defined by:

𝐹1 = 2 ∗

𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 ∗ 𝑟𝑒𝑐𝑎𝑙𝑙
𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 + 𝑟𝑒𝑐𝑎𝑙𝑙

(6)

Harmonic mean is used in place of an arithmetic mean because the harmonic mean
strongly penalizes extreme values (e.g., with precision = 1 and recall = 0, the arithmetic
mean is equal to 0.5 but the F1 score is 0). The F1 score ranges from 0 to 1 with higher
performing models having greater F1 scores.
The ROC curve is a probability curve plotted with the true positive rate against the
false positive rate, providing information about the model performance for binary
classification at various decision threshold settings. The AUC measures the area under
the ROC curve ranging from 0 to 1. When AUC is close to 0, the model is reciprocating
the result (i.e., predicting classes as the opposite values). When AUC is close to 1, the
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model has very good measure of separability and accuracy. When AUC is 0.5, the model
has no class separation capacity at all. [107]
The precision-recall curve is a probability curve plotting the recall against the
precision for various decision threshold settings. The PRAUC refers to the area under the
precision-recall curve. As a result of recall increasing, precision decreases. PRAUC
metrics can be useful in determining the optimal threshold for precision/recall balance.
[108]
When building a binary classification model, it is important to consider multiple
accuracy metrics to determine the decision threshold. The F1-score is an important metric
in most binary classification problems; in particular, models where the positive class is
more important. When data is relatively balanced between classes, the ROC AUC metric
is an appropriate measure of model accuracy. However, when data is heavily imbalanced,
the PRAUC is more appropriate. [105], [109], [110]
Threshold is one of the many important hyperparameters that must be tuned for a
machine learning model. Hyperparameters refer to parameters whose values are
determined prior to the learning process (e.g., threshold, learning rate, maximum number
of features) in contrast to parameters determined via training (e.g., node weights). Each
specific machine learning algorithm requires unique hyperparameters to be tuned to
improve the speed and quality of the learning process. Performance measures for training
and test error values guide the hyperparameter tuning process. [102]
Random search and grid search are simple and commonly used search optimization
algorithms. In random search, the search space (or volume to be searched where each
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dimension represents a hyperparameter and each observation represents one possible set
of hyperparameters) is a bounded domain of possible hyperparameter values and
combinations are randomly sampled in that domain. Grid search, in contrast, evaluates
every single possible combination in the domain.
Training error refers to any measure of error (i.e., proportion of incorrectly predicted
values) for the training set. The test error, or generalization error, refers to the expected
value of the error on a previously unseen dataset. When optimizing the performance of a
machine learning model, we want to both minimize our training error and the gap
between the training and test errors. When the training error is too large, it results in
underfitting of the data. When the magnitude of difference between the training and test
error is too large, overfitting occurs. [102]
In supervised machine learning models, the error should be minimized while
learning from training data. The loss function (i.e., error function) quantifies the
associated error for a single training example. The cost function, sometimes used
synonymously with the loss function, describes the average loss over the entire training
set. Optimization strategies such as gradient descent aim to minimize this cost function.
In addition to the importance of optimizing a model, regularization of the model should
also be considered. Regularization refers to any modification that is made to an algorithm
with the intended purpose of reducing the test error but not the training error. If the
training data contains too much noise, there is a risk of overfitting the data and the model
will not generalize well to future dataset testing. [102] Often, the regularizer is in the
form of a penalty added to the loss function. Regularization effectively discourages
overly flexible models and the resulting risk of overfitting. To successfully achieve this
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goal, a regularizer should reduce model variance without increasing bias (i.e., our model
should be generalizable to previously unseen data in a test dataset without overly
increasing error due to false assumptions). [111] The variance of an estimator 𝜃 is
equivalent to the square of the standard error of 𝜃 where:
𝑆𝐸(𝜇̂ 𝑚 ) =

𝜎
√𝑚

(7)

while the bias of an estimator 𝜃 is defined as 𝑏𝑖𝑎𝑠(𝜃̂𝑚 ) = 𝔼(𝜃̂𝑚 ) − 𝜃, where the
expectation 𝔼(𝜃̂𝑚 ) is over samples from a random variable and 𝜃 is the true value of 𝜃.
[105]
Common examples of regularization include applying an L1 or L2 vector norm
penalty to the network optimization such as the use of Ridge regression in linear models
or penalizing a neural network loss function for large weights. The L1 norm, also known
as the Lasso, aims to shrink the estimated coefficients of the loss function. For an
example linear regression:
𝑌 ≈ 𝛽0 + 𝛽1 𝑥1 + 𝛽2 𝑥2 + ⋯ + 𝛽𝑝 𝑥𝑝

(8)

fitted using the residual sum of squares (RSS) loss function:
𝑝

𝑛

2

𝑅𝑆𝑆 = ∑ (𝑦𝑖 − 𝛽0 − ∑ 𝛽𝑗 𝑥𝑖𝑗 )
𝑖=1

(9)

𝑗=1

we are able to shrink our coefficients by minimizing the RSS using a tuning
parameter λ such that:
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𝑛

𝑝

2

𝑝

𝑝

∑ (𝑦𝑖 − 𝛽0 − ∑ 𝛽𝑗 𝑥𝑖𝑗 ) + 𝜆 ∑|𝛽𝑗 | = 𝑅𝑆𝑆 + 𝜆 ∑|𝛽𝑗 |
𝑖=1

𝑗=1

𝑗=1

(10)

𝑗=1

The L2 norm (also referred to as Ridge regression) also shrinks the coefficients of
the model using λ, however we penalize all coefficients (𝛽𝑗2 ) rather than only the high
coefficients (|βj|) as in the L1 norm:
𝑛

𝑝

2

𝑝

𝑝

∑ (𝑦𝑖 − 𝛽0 − ∑ 𝛽𝑗 𝑥𝑖𝑗 ) + 𝜆 ∑ 𝛽𝑗2 = 𝑅𝑆𝑆 + 𝜆 ∑ 𝛽𝑗2
𝑖=1

𝑗=1

𝑗=1

(11)

𝑗=1

In the case of the L2 norm, the least important coefficients will be shrunk closely to
zero, but never equal to exactly zero. Thus, our final model will still include all
predictors. However, the L1 norm penalizes some coefficients to exactly zero at large
enough λ, effectively removing these predictors from the model. The tuning parameter λ
must be carefully selected to balance bias and variance. [105], [111]
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2.4.4

Hyperparameter tuning

To best select the value of λ and other algorithm hyperparameters, there must be a
validation dataset containing observations not included in the training dataset. When
optimizing hyperparameters on the training data, there is a risk of overfitting and
subsequent poor generalization of the model to unseen data. To circumvent this issue, the
training dataset is split into two subsets—one to learn the parameters and another
validation set to estimate the test error after training to update the hyperparameters. After
hyperparameter optimization is complete, the error on the test set can be determined.
In addition to hyperparameter tuning and regularization, it is also important to
consider the effect of our feature space on model capacity (i.e., underfitting and
overfitting the model). When there are not enough features, underfitting results. When we
have more features than observations, overfitting is risked. The difficulty of identifying
the optimal number of features while balancing the consequences of each extreme is
often referred to as the curse of dimensionality. As the dimension of our data increases,
the data becomes “sparser” and more difficult to analyze. [112] Additionally, the risk of
introducing noise (misleading or irrelevant data) also increases. The amount of training
data necessary must also increase to mitigate these issues, substantially increasing the
calculation time complexity. The number of training data needed increases exponentially
in response to the number of features added—this becomes increasingly computationally
complex and loses real-world value.
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2.4.5

Feature selection methods

As a solution, dimensionality reduction is needed. Other benefits of reducing the
dimension of our data (e.g., feature selection and feature engineering strategies) include
decreasing the time-complexity and required memory storage to train the algorithm.
Feature selection involves the identification of relevant features to be selected for model
training. Feature engineering refers generally to the process of extracting useful features
from raw data. [28], [112]
Commonly used feature selection strategies include those based upon variance
threshold, univariate feature selection (e.g., Pearson correlation, ANOVA testing, or Chisquare algorithms in which the best k features, or a top percentile of features, are selected
based off the information provided by these statistical measures), principal component
analysis (PCA), linear discriminant analysis (LDA), multi-dimensional scaling (MDS),
locally linear embedding (LLE), and t-distributed stochastic neighbor embedding (tSNE). PCA and LDA are both based on linear transformations of data, where PCA
focuses on features with maximum variance and LDA aims to maximize class
separability. In contrast, MDS, LLE, and t-SNE are examples of non-linear manifold
strategies that are capable of projecting complex data shapes into lower dimensional
space while best preserving shape and Euclidean distance of data points. The
mathematical basis and strategy for these dimensionality reduction techniques varies
highly depending on the original data format and algorithm choice. [113], [114]
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For non-structure-based feature selection methods in the machine learning models
used for this project, the primary techniques presented for feature selection are recursive
feature elimination (RFE) and partial least squares (PLS; including orthogonal partial
least squares; O-PLS). RFE refers to a wrapper style algorithm in which features are
ranked and selected by importance, where importance is determined by machine learning
algorithm at the core of the model. [115], [116] This machine learning algorithm, such as
logistic regression or random forest, is “wrapped” by RFE and features are ranked by a
measure of feature importance (e.g., the coefficients of logistic regression or impuritybased node probability in random forest). The least important features are removed from
the model, the model is re-fit, and this process is repeated until the user-specific number
of features remains.
PLS aims to extract features from both the input matrix 𝑿 and output matrix 𝒀 such
that the covariance between all extracted factors is maximized. PLS is advantageous over
PCA in its ability to address multi-colinearity (i.e., two or more data features are
correlated with one another). [117]–[121] In comparison to PCA, which only considers
the matrix of input variables without the context of the output data matrix, PLS considers
the relationship between the input and output. The goal of PLS is to find a linear
decomposition of 𝑿 and 𝒀 such that:
𝑿 = 𝑻𝑷𝑇 + 𝑬

(12)

𝒀 = 𝑼𝑸𝑇 + 𝑭

(13)

where 𝑻 represents the 𝑿-factors, 𝑼 represents the 𝒀-factors, 𝑷 represents the 𝑿loadings (i.e., the linear coefficients that link terms to the factors), 𝑸 represents the 𝒀28

loadings, 𝑬 represents the 𝑿-residuals, and 𝑭 represents the 𝒀-residuals. In factor analysis
techniques such as PCA and PLS, loadings refer to the correlation coefficients between
the variable and factor. Factor loading shows the variance explained by a variable on its
given factor. The residuals, or error terms, are used to evaluate the accuracy of the factor
analysis. The linear decomposition of 𝑿 and 𝒀 is computed to maximize the covariance
between 𝑻 and 𝑼; by extracting the factors that successively achieve this task, the best
explanation of the 𝑿-space, 𝒀-space, and the greatest correlation between 𝑿 and 𝒀 are
also maximized.
Each extracted 𝑋-score is a linear combination of 𝑿; i.e., the 1st 𝑿-score t of 𝑿 is
equal to 𝑿𝑤, where 𝑤 is the eigenvector corresponding to the 1st eigenvalue of 𝑿𝑻 𝒀𝒀𝑻 𝑿.
The same is true for the 1st 𝑌-score 𝑢 = 𝒀𝑐 where 𝑐 is the eigenvector corresponding to
the 1st eigenvalue of 𝒀𝑻 𝑿𝑿𝑻 𝒀. After factors are extracted for each ith iteration, 𝑋 and 𝑌
are deflated to equal 𝑿𝑖 = 𝑿 − 𝑡𝑡 T 𝑿 and 𝒀𝑖 = 𝒀 − 𝑢𝑢T 𝒀. This process is repeated until
all possible latent factors 𝑡 and 𝑢 are extracted, i.e., when 𝑋 is reduced to a null matrix.
[117], [118], [122], [123]
O-PLS is a method based on the PLS algorithm that uses orthogonal signal
correction to maximize the explained covariance for the 1st latent factors while the future
factors describe variance in the predictors that is orthogonal to the response variables,
i.e., uncorrelated to the response. O-PLS functionally differs from PLS in that the O-PLS
algorithm filters out noise in the data by separately modeling variations of the 𝑿-factor
features that are correlated and uncorrelated to the 𝒀-factor features, respectively. This
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key difference ultimately reduces model complexity, lowers the number of extracted
factors, and allows for analysis of the source of orthogonal variation. [121], [124]
The O-PLS linear decomposition is mathematically similar to PLS, but differs in the
inclusion of the orthogonal 𝑿-factors and 𝑿-loadings via a 𝑻𝑜𝑟𝑡ℎ 𝑷𝑇𝑜𝑟𝑡ℎ term such that:
𝑿 = 𝑻𝑷𝑇 + 𝑻𝑜𝑟𝑡ℎ 𝑷𝑇𝑜𝑟𝑡ℎ + 𝑬
𝒀 = 𝑼𝑪𝑇 + 𝑭

(14)

(15)

It is of note that while neural networks can be improved upon by preprocessing with
a feature selection algorithm when appropriate, this is not always necessary as neural
networks are capable as functioning as feature selection algorithms in themselves. Neural
networks may identify salient features via backpropagation, updating the weights of the
neural network. The mechanism of backpropagation and structure of neural networks is
further described in further introductory Neural Network sections. [99], [102]
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2.4.6

Machine learning algorithms

Many commonly used machine learning algorithms are implemented in the research
plan proposed as predictive classifiers including regression, decision trees, AdaBoost,
support vector machines (SVMs), and neural networks. [102], [125]–[132]
2.4.6.1

Regression

. Linear regression is a common supervised machine learning algorithm with a
constant slope and a continuous output variable. Linear regression models are often
presented in the slope-intercept form:
𝑦 = 𝑚𝑥 + 𝑏

(16)

where 𝑦 is the output variable determined by a variable (or feature) 𝑥 multiplied by
our slope coefficient 𝑚 (otherwise referred to as the weight associated with each feature)
and 𝑏 is the y-intercept (otherwise referred to as the bias) that offsets our prediction. The
goal of the algorithm is to predict the correct values for 𝑚 and 𝑏 to approximate the line
of best fit. (Figure 7) [102], [105]
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Figure 7. Linear regression model. An example of a linear regression
line of best fit estimating the relationship between an input variable x and
output variable y for a random dataset.

To optimize the weights of the model, a cost function is used. This process is
generally applicable to any machine learning algorithm, but linear regression will be used
as an example. Consider the MSE cost function applied to a linear regression model:
𝑛

1
2
𝑀𝑆𝐸 = ∑(𝑦𝑗 − 𝑦̂𝑗 )
𝑛

(17)

𝑗=1

where 𝑦𝑖 = 𝑚𝑥𝑖 + 𝑏 for each 𝑖 𝑡ℎ true value of 𝑥 and 𝑦̂𝑖 = 𝑚𝑥𝑖 + 𝑏 is the 𝑖 𝑡ℎ
prediction for each value of 𝑦𝑖 . MSE measures the average squared difference between
the actual and predicted output values for each input value. The MSE cost changes with
the current set of weight and should be minimized to improve the accuracy of the model.
[102], [103]
Gradient descent is used to calculate the gradient of the cost function. The error
associated with the weight is minimized via using the derivative of the cost function to
compute the gradient (i.e., the slope of the cost function) and error is subsequently
adjusted to move in the opposite direction of the gradient. The gradient can be split into
the partial derivatives of the function of 𝑥 and the function of 𝑚 and 𝑏:
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2

(𝑦𝑖 − (𝑚𝑥𝑖 + 𝑏)) = 𝐴(𝐵(𝑚, 𝑏))
𝐴(𝑥) = 𝑥 2

(18)

(19)

𝑑𝑓
= 𝐴′ (𝑥) = 2𝑥
𝑑𝑥

(20)

and
𝐵(𝑚, 𝑏) = 𝑦𝑖 − (𝑚𝑥𝑖 + 𝑏) = 𝑦𝑖 − 𝑚𝑥𝑖 − 𝑏
𝑑𝑥
= 𝐵 ′ (𝑚) = 0 − 𝑥𝑖 − 0 = −𝑥𝑖
𝑑𝑚
𝑑𝑥
= 𝐵 ′ (𝑏) = 0 − 0 − 1 = −1
𝑑𝑏

(21)

(22)

(23)

Combining these parts via the Chain rule yields:
𝑑𝑓 𝑑𝑓 𝑑𝑥
=
𝑑𝑏 𝑑𝑥 𝑑𝑏

(24)

𝑑𝑓
= 𝐴′ (𝐵(𝑚, 𝑓))𝐵 ′ (𝑚) = 2(𝑦𝑖 − (𝑚𝑥𝑖 + 𝑏)) ⋅ −𝑥𝑖
𝑑𝑚
𝑑𝑓
= 𝐴′ (𝐵(𝑚, 𝑓))𝐵′ (𝑏) = 2(𝑦𝑖 − (𝑚𝑥𝑖 + 𝑏)) ⋅ −1
𝑑𝑏

(25)

(26)

Thus the gradient of the cost function is computed as:
𝑑𝑓
1
∑ −𝑥𝑖 ⋅ 2(𝑦𝑖 − (𝑚𝑥𝑖 + 𝑏))
𝑑𝑚
𝑁
′ (𝑚,
𝑓
𝑏) = [ ] = [
]
1
𝑑𝑓
∑ −1 ⋅ 2(𝑦𝑖 − (𝑚𝑥𝑖 + 𝑏))
𝑁
𝑑𝑏
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(27)

1
∑ −2𝑥𝑖 (𝑦𝑖 − (𝑚𝑥𝑖 + 𝑏))
𝑁
= [
]
1
∑ −2(𝑦𝑖 − (𝑚𝑥𝑖 + 𝑏))
𝑁

(28)

The model is trained via iterating through the dataset multiple times to improve the
prediction via updating the weight and bias values in the direction indicated by the
gradient of the cost function. [133], [134]
Training is considered complete based on an acceptable error threshold, the cost
function converging (i.e., the algorithm ceases to further reduce cost with further
iterations), or a set number of iterations. In addition to hyperparameters such as number
of iterations, we also must choose a learning rate. The learning rate refers to the step size
used in gradient descent. A greater value will learn faster but risks a suboptimal final
prediction, while a smaller learning rate takes longer to converge. A learning rate that is
too small risks the cost function never converging. [102], [105]
Lastly, the trained model is evaluated on a test set of data to evaluate its
generalization error and predictive ability via measures of accuracy. This general process
of tuning hyperparameters, training the model to update weights and reduce loss, and
testing the model on a previously unseen dataset can be generally applied to other
machine learning algorithms with different structures as well. [102]
In a multivariate regression (i.e., multiple input variables or features), the model
resembles:
𝑓(𝑥1 , 𝑥2 , … , 𝑥𝑛 ) = 𝑤1 𝑥1 + 𝑤2 𝑥2 + ⋯ + 𝑤𝑛 𝑥𝑛 + 𝑏
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(29)

Each input feature 𝑥𝑛 has an associated weight that must be optimized in the
learning process. As the number of features increases (i.e., our input dimensionality
increases), the computational cost of calculating the gradient also increases. In addition to
dimensionality reduction strategies, rescaling the data also aids in reducing time
complexity. Common rescaling techniques include normalization (i.e., rescaling values to
a range of [0,1]) and standardization (i.e., rescaling values to have a mean of 0 and
standard deviation of 1). [105]
Linear regression models are only appropriate when the output variable is
continuous. In contrast, logistic regression models are used when the output variable is
categorical. Logistic regression models have the form:

log(𝜂) =

1
1 + 𝑒𝑥𝑝 (−η)

(30)

Logistic regression models output values between 0 and 1. (Figure 8)

Figure 8. Logistic regression model. A logistic regression model has a
characteristic sigmoidal ‘S’ shape predicting output y values between 0
and 1 from an input value x.
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The logistic regression model finds a decision boundary, or threshold, to determine
what class prediction each value will belong to. For example, in a binary classification
with outputs [0,1], a threshold value of 0.5 corresponds to output values below 0.5
belonging to the ‘0’ class and otherwise belonging to the ‘1’ class. Linear and logistic
regression models have many real-world similarities in that while they are both widely
used for appropriate applications, they are often not appropriate for handling more
complex data sets with higher dimensionality. [105]
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2.4.6.2

Decision tree-based models.

Random forest is a supervised learning model that has gained popularity for its
applicability and interpretability. Random forest can be used for prediction of both
continuous and categorical output variables. In random forest models, the “forest”
ensemble of decision trees built are trained via bagging to increase overall prediction
accuracy. (Figure 9) [125], [126]

Figure 9. Decision tree and random forest models. A Schematic example of a simple decision tree. Starting from Row 1,
there is one decision to be made with three possible outcomes. Outcomes #1 and #3 each have two resulting potential
outcomes, while outcome #2 has three potential outcomes. B Schematic example of a simple random forest model in which
the final prediction is generated via bagging of multiple decision trees.

Decision trees are a decision analysis tool that uses a branched flowchart model of
decisions and their possible outcomes with associated probabilities. [105], [135], [136]
The structure of a decision tree results in straightforward measurability and
interpretability for the relative feature importance of each feature on the prediction. In a
decision tree, each node represents the possible values of each attribute, each branch
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represents the outcome of the decision, and each leaf node represents a class label (i.e.,
the final decision output after considering all features). A node that has no children is
referred to as a leaf. Feature importance can be calculated via analyzing the extent to
which each tree node for a given feature reduces impurity (the probability of incorrectly
classifying a randomly chosen observation given the class distribution of the dataset)
across all trees. Feature importances are scaled so the total sum of all importance is equal
to 1. [102], [105] Many other variations of decision tree classifiers similar to random
forest exist in the literature. These similar algorithms include the scikit-learn meta
estimators that fit a number of decision trees on various subsets of the original data and
improves predictive accuracy via aggregating or averaging individual predictions to form
a final prediction, such as the bagged trees classifier and extra trees classifier. [115]
Random forest models are advantageous compared to simple decision trees despite
the increased computational cost because the algorithm randomly selects a subset of data
and features to build several decision trees and averages the results, increasing overall
prediction accuracy. Additionally, random forest is less prone to overfitting than simple
decision tree models. [105], [123]
Random forests are controlled by hyperparameters such as number of estimators (the
number of trees used), maximum number of features used, the minimum number of
leaves required to split a node, and out-of-bag (oob) sampling in cross-validation. [137]
In contrast to the bagging method used in random forest, adaptive boosting
(AdaBoost) combines the output of other ‘weak learner’ algorithms (often, but not
always, decision trees) into a weighted sum that represents the final output of the boosted
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classifier. [127], [128] The AdaBoost classifier selects only the features known to
improve the predictive accuracy of the model. Boost classifiers can be represented via:
𝑇

𝐹𝑇 (𝑥) = ∑ 𝑓𝑡 (𝑥)

(31)

𝑡=1

where 𝑓𝑡 is a weak learner that takes an input 𝑥 and returns a class label. The boosted
classifier is trained so that the sum training error 𝐸𝑡 is minimized:
𝐸𝑡 = ∑ 𝐸[𝐹𝑡−1 (𝑥𝑖 ) + 𝛼𝑡 ℎ(𝑥𝑖 )

(31)

𝑖

Here 𝐹𝑡−1 (𝑥) represents the boosted classifier up until the previous training iteration,
𝐸[𝐹] is some error function, and 𝛼𝑡 ℎ(𝑥𝑖 ) is a weak learner 𝑓𝑡 (𝑥) that is being added to
the final boosted classifier wherein at each iteration 𝑡, each 𝑓𝑡 (𝑥) is assigned a
coefficient 𝛼𝑡 and produces an output hypothesis ℎ(𝑥𝑖 ). (Figure 10) Training iterations
are informed by weights {𝑤𝑖,𝑡 } equal to 𝐸(𝐹𝑡−1 (𝑥𝑖 )). [102]
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Figure 10. AdaBoost model. A data set of blue ‘+’ symbols and red ‘-‘ symbols is classified by a cartoon representation of
the AdaBoost algorithm. In each iteration, a “weak” learner attempts to separate the data. These “weak learners” are
combined into a final weighted classifier to produce the strongest separation result.
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2.4.6.3

Support vector machines.

SVMs are supervised learning models that are often applied to classification
problems. SVMs aim to find a hyperplane or set of hyperplanes that best separate the data
points into their respective classes. In geometry, a hyperplane refers to a subspace whose
dimension is one less than that of its surrounding space (e.g., in a three-dimensional
space, two-dimensional hyperplanes exist). The optimal hyperplane is known as the
maximum-margin hyperplane, defined as the hyperplane that has the largest distance to
the nearest data point of each class. (Figure 11)

Figure 11. Support vector machine. A dataset is separated by a hyperplane. In a SVM, the maximummargin hyperplane is used to maximize the distance between each class and the hyperplane, chosen based
on the minimum test error possible. As an example, the hyperplane for 3-dimensional data is 2dimensional.
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The maximum-margin hyperplane is chosen as it typically results in the lowest test
error for the classifier. Given a training dataset {(𝑥1 , 𝑦1 ), … , (𝑥𝑛 , 𝑦𝑛 )} where each 𝑥𝑖
represents a vector of data features for a given 𝑖 𝑡ℎ observation and 𝑦𝑖 represents the
corresponding discrete class label for said observation (e.g., 0 and 1 for a binary
classification problem). A given hyperplane containing the set of points 𝒙 can be written
in the form:
𝒘𝑇 𝒙 − 𝑏 = 0

(32)

where 𝒘 is the normal vector to the hyperplane and 𝑏 is the bias term. For a binary
classification example, if the data are linearly separable, two hyperplanes are selected that
separate the two classes of data such that the distance between said planes (i.e., the
margin) is maximized. The maximum-margin hyperplane lies at the halfway point of the
margin. The SVM is optimized via minimization of ‖𝒘‖. In cases where the data are not
linearly separable, techniques such as the hinge loss function can penalize for data points
𝑥𝑖 on the incorrect side of the margin where the function equals:
max (0,1 − 𝑦𝑖 (𝒘𝑇 𝒙𝑖 − 𝑏))

(33)

such that the function equals 0 when 𝑥𝑖 is correctly classified while for incorrectly
classified observations, the function’s value is proportional to the distance from the
margin. [129], [130]
Non-linear classifiers can also be constructed via application of the kernel trick,
including common examples such as polynomial kernels:
𝑘(𝑥
⃗⃗⃗⃗𝑖 , ⃗⃗⃗
𝑥𝑗 ) = (𝑥
⃗⃗⃗⃗𝑖 ⋅ ⃗⃗⃗
𝑥𝑗 )
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𝑑

(34)

and the radial basis function [105], [130]:
2

𝑘(𝑥
⃗⃗⃗⃗𝑖 , ⃗⃗⃗
𝑥𝑗 ) = exp (−𝛾‖𝑥
⃗⃗⃗⃗𝑖 − ⃗⃗⃗
𝑥𝑗 ‖ ) for 𝛾 > 0

43

(35)

2.4.7

Neural Networks

In 1958, Rosenblatt created the single-layer perceptron. [131] A perceptron,
essentially a single node (also called a neuron) activated by the Heaviside step function,
takes the form:
𝑓(𝑥) = {

1 if 𝒘 ⋅ 𝒙 + 𝑏 > 0,
0 otherwise

(36)

where the input 𝒙 is mapped to an output value 𝑓(𝑥) and 𝒘 is a vector of real-valued
weights and 𝑏 is the bias. While the single-layer perceptron is the simplest feedforward
neural network, modern networks typically contain multiple functions. Feedforward
neural networks, also known as multilayer perceptrons, are the simplest modern form of a
neural network and the foundation upon which other neural networks with increasing
complexity are created. The term ‘feedforward’ refers to the way that information flows
or transfers through the model via the initial input 𝒙 via a series of intermediate functions
to produce the output 𝑓(𝑥). The function is referred to as a ‘network’ because the input
undergoes a series of transformations via a chain of connected functions typically
represented as a graph of nodes. (Figure 12) The term ‘neural network’ comes from the
idea that neural networks are loosely modeled off of the structure of biological neurons,
but this is considered to be a misnomer as the similarities are limited. [99], [102], [105],
[138], [139]
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Figure 12. Neural network structure. A cartoon schematic showing the generalized structure of
a deep neural network containing an input layer, three hidden layers, and one output layer. Data
from the single input node is transformed by an activation function at each node in the following
layer. Each connection is weighted, and these weights are adjusted as the network learns.

Each ‘neuron’ in the neural network is represented as a node in the network. The
overall length of the chain of nodes gives the depth of the network. Generally, neural
networks with more than two layers are referred to as deep neural networks. For example,
we may have three neurons representing the functions 𝑓 (1) , 𝑓 (2) , and 𝑓 (3) connected via
a network to form 𝑓(𝑥) = 𝑓 (3) (𝑓 (2) (𝑓 (1) (𝒙))). The network is structured into layers
containing nodes that act in parallel where each node represents a vector-to-scalar
function. The dimensionality of each layer is called the width of the network. The layers
between the input layer and output layer are referred to as hidden layers, named in
reference to the ‘black box’ nature of neural networks. As data is passed through each
layer and the neural network begins to approximate the form of 𝑓(𝑥), the output for each
layer is not shown; rather, it is simply fed into the next layer until the final output layer.
The nodes in each layer are connected and each connection is assigned a weight
representing its relative importance to the model. The neurons within the hidden layers
typically have multiple input and output connections. If every neuron in a layer connected
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to each neuron in the following layer, the layers are fully-connected. In contrast, when a
group of neurons in one layer are all condensed and connected into the same neuron in
the following layer, it is called pooling. Recurrent networks, in contrast to feedforward
networks, allow connections between neurons in the same layer or previous layers. [99],
[102], [105], [138], [139]
The hyperparameters for a feedforward neural network include learning rate, depth,
width, and batch size. More complex neural network structures, such as recurrent and
convolutional neural networks, have their own additional unique set of hyperparameters.
[140]
In a feedforward network with hidden layers, activation functions are used to
compute the hidden layer values. In a neuron model consisting of an input 𝒙 with bias 𝑏
and a weight of 𝒘 summarized together as 𝑧 and an activation function 𝜑 that performs a
non-linear transformation of 𝑧. The resulting output of the neuron model can be described
as:
𝑦 = 𝜑(𝑧) = 𝜑(𝒘𝑇 𝒙 + 𝑏)

(37)

Many activation functions exist. Commonly found activation functions are
summarized in Table 1. [102]

Table 1. Common activation functions for neural networks, their first derivatives, and ranges.
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The computation of gradients and updating of weights in neural networks is
performed via an algorithm called backpropagation. Backpropagation calculates the
gradient of the cost function associated with a given set of weights corresponding to each
connection of the network. Backpropagation involves computing the gradient of the loss
function via the chain rule one layer at a time, passing through the network backwards
starting from the last layer to prevent unnecessarily repetitive calculations within the
Chain rule. This method is much more efficient than a direct computation of the gradient
with respect to each individual weight. Via this process, weights are iteratively updated
with each epoch of training such that the weights of the least important neurons are
decreased and the weights of the more important neurons are increased proportionately.
[102], [141]–[143]
There are many specialized types of neural networks, including the convolutional
neural network (CNN). CNN have been previously applied to biomedical problems with
success due to their ability to analyze three-dimensional molecular structure data. [19],
[21], [98], [139] CNN utilize convolutional and pooling layers with local connectivity
between neurons (i.e., neurons are only connected to the nearby neurons in the next layer
rather than fully connected). All of the connections between a group of locally connected
neurons, called local receptive fields, use a set of weights denoted as a kernel. A kernel
will be shared with all of the other neurons that connect to their local receptive fields and
the results are stored in a matrix called the activation map. This process is described as
weight sharing. Weight sharing and the local connectivity property allow a CNN to
handle data with high dimensions. [99], [102], [144]–[147] Pooling layers aim to reduce
the input dimension and aid in improving the generalization of the network. The pooling
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layer scans the entire input in the same manner as a kernel in a convolutional layer. The
most common type of pooling is max pooling, where the maximum value within each
specified sub-window is extracted across the activation map. For example, a pooling
layer with a stride of two and window size of two will half the size of the input
dimension. [148]–[151] Figure 13 represents the overall structure of a CNN.

Figure 13. Convolutional neural network architecture. A cartoon schematic showing the generalized structure of a
convolutional neural network containing pooling layers. Convolutional layers extract high-level features such as edges in an input
image or gradient. Added convolutional layers contribute to a higher level of feature extraction. Pooling layers reduce the spatial
size of the convolved features to decrease the associated computational cost necessary via extracting only the dominant features.
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2.5

Bioinformatics methods.

2.5.1

Molecular dynamics simulation

Molecular dynamics simulation and molecular modeling technology have been key
techniques used in the advancement of biochemical research; in particular, SBDD.
Ligand docking is a core modeling protocol valued for its significant time- and costefficient advantage over traditional biochemical protocols. While computational
advancements have improved the time complexity and accuracy of simulation techniques,
high dimensionality and throughput capacity are still concerns when using modeling
alone in bioinformatic studies. [94] Recent molecular dynamics studies have shown
success at elucidating the structural details of specific molecular interactions, while large
scale studies have been increasingly dependent on machine learning methods. [35], [92],
[96], [152], [153]
Within recent years, machine learning tools capable of handling “big data” problems
have been applied to computational biochemistry research to address the large feature
space and amount of output data produced when studying molecular interactions. [19]–
[22], [98], [100], [138], [154], [155] Augmenting biomedical research with machine
learning has become increasingly common over the last thirty years as high throughput
techniques advance and produce large amounts of data. Machine learning is often applied
to the fields of systems biology, genomics, proteomics, pharmacology/toxicology, and
structural biochemistry. [138] The field of computational toxicology often uses
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quantitative structure-activity relationship (QSAR) modeling to predict the activity of a
compound against a set of biological targets. [156] QSAR programs often use regression
models to predict the biological activity of a chemical against protein receptors trained on
experimental assay data. Many QSAR models use ToxCast data as training sets and focus
on respiratory, skin, hepatic, renal, or neural toxicity. [157]–[161] Within the realm of
structural biochemistry, machine learning programs have proven useful for protein
structure prediction and classification as well as interpretation of molecular dynamics
output data. [98], [155], [162]
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2.5.2

Machine learning models for bioinformatics

Machine learning programs for molecular applications use chemical descriptors as
features to describe the data and aid in the identification of a pattern within the data.
[163] These descriptors may be macromolecule specific (e.g., amino acid descriptors for
proteins) or generalized physical chemistry descriptors such as electron density,
nucleophilicity, charge, or topological indices. Molecular topology describes the
geometry and structure of a chemical given the atomic positions and chemical bonding
behavior of a given molecule. Topological indices are very useful features in machine
learning applications where the goal is to predict biological activity based on the
chemical structure of a molecule. [164], [165]
Many algorithms have been trained specifically for structural analysis of protein
structure and function, including the recent SSnet [22], DeepScreen [20], DeepAtom
[19], and DeepConv [21] methods described in Specific Aim 1. Despite the established
progress of augmenting protein biochemistry research with machine learning, current
models often produce suboptimal accuracies for reliable clinical translation and few
examples of transfer learning to a specific clinical application exist. [139] GPCR-focused
models primarily include QSAR analysis, class prediction, and evolutionary biology
studies but the field predominately still relies on computationally-expensive molecular
dynamics methodology. [29], [84], [166]–[168] Within the previous two years, a limited
number of GPCR-ligand interaction studies utilizing machine learning have been
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published, demonstrating the potential success for a similar model to be developed
specifically against a given GPCR subtype. [169], [170]
Classification and behavior prediction of protein receptors may use feature
descriptors based on sequence, structure, or both. Tens of thousands of protein chemical
descriptors exist, and a complete comparison of all available feature groups and strategies
is beyond the scope of this work. [163], [171]–[177] Protein sequence descriptors may
include polarity, charge, and size of amino acids. In contrast, protein structural features
take into account the three-dimensional shape of a protein and the intramolecular
interactions between amino acids as well as the protein interactions with solvent. [164],
[178] Protein structural features may offer more useful information than sequence alone
as structure is an important determinant of function. [179]–[181]
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2.5.3

Anisotropic Network Model

Atomic interaction data from normal mode analysis models such as the Gaussian
Network Model (GNM) and the Anisotropic Network Model (ANM) provide detailed
structural information that is directly related to the molecular dynamics and function of a
protein comparable to molecular dynamics simulation at a fraction of the computational
cost. [182]–[191] These elastic network modeling tools are specifically tuned to examine
proteins via the relationship of force constants versus the interparticle distance between
the residue alpha carbons (𝐶𝛼 ). In these models, the protein is represented as an elastic
mass-and-spring network where each network node is a residue’s 𝐶𝛼 and each 𝐶𝛼 − 𝐶𝛼
interaction is represented as a spring, based on the concept that the atomic fluctuations in
a biomolecule are subject to harmonic potential much like masses connected to springs,
pendulums, or acoustics. The harmonic potential between all interacting 𝐶𝛼 nodes
describes the internal motions of the “spring” connecting each 𝐶𝛼 − 𝐶𝛼 pair. The ANM is
an augmentation of the GNM as the GNM does not account for directionality of
fluctuation while the ANM uses three-dimensional atomic coordinates to account for
directionality when describing the compression and expansion of the spring. [184], [186]
In the GNM, there is no directional preference or three-dimensional character of motion
accounted for, therefore, the molecule is views as a collection of 𝑁 nodes (i.e., one for
each residue). The resulting ensemble has 𝑁 − 1 independent modes, where a “normal
mode” or harmonic refers to the pattern of motion in an oscillating system in which all
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system components move sinusoidally at the same frequency. In the three-dimensional
system of an ANM, 3𝑁 − 6 modes are obtained. It has been demonstrated in the
literature that atomic fluctuations are generally anisotropic, or capable of changing
properties in different directions (e.g., properties such as absorbance, conductivity, and
polarizability are anisotropic in nature). These directional motions are directly related to
the biological functions of proteins. Cumulatively, this evidence supports the notion that
the meticulously detailed nature of the information provided by the ANM balanced with
the relatively simple time complexity of calculations provided by the lack of necessity to
differentiate between the chemical differences of specific amino acids makes feature
generation and feature engineering via the ANM an advantageous approach for protein
structure classification models. [184], [185], [192]
The ANM is useful in describing the atomic fluctuations and molecular dynamics of
proteins to better describe their three-dimensional structural and functional
characteristics. This information can be used to guide molecular dynamics simulations as
well as provide a rich source of features to be used in training machine learning models.
[185] Normal mode analysis methods like the ANM are advantageous over full scale
molecular dynamics simulation because they are capable of representing large scale
atomic behavior at a fraction of the computational cost with robust results. [164], [193],
[194] Using features provided by ANM analysis has shown promise as a comparable
method for describing protein structure in machine learning models to the wellestablished RMSD and TM-scoring strategies. [192] In general, the ANM is more
accurate for globular proteins than non-globular, proteins with high-resolution structures,
buried residues as compared to surface residues, and polar residues as compared to
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hydrophobic residues. [185] The ANM has shown success in the analysis of the structural
characteristics of many proteins including hemoglobin [195], amylase [184], HIV-1
reverse transcriptase [182], [196], DNA polymerase [197], CoV spike protein [198], and
numerous GPCRs [199], [200].
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2.5.4

Protein structural comparison methods

Protein structure can be described independently or in comparison to other protein
structures. By comparing individual structures to all others in a dataset, it is possible to
quantify structural variation and identify the most unique regions of the structural
landscape. [192] Variation can be determined via measures such as root-mean-square
deviation of atomic positions (RMSD), TM-score, and variance threshold-based feature
importance ranking of chemical descriptors like those obtained from normal mode
analysis. [192], [201]
RMSD is a measure of the distance between pairwise atomic coordinates between
two superimposed protein structures. RMSD is defined by:

𝑛

1
𝑅𝑀𝑆𝐷 = √ ∑ 𝑑𝑖2
𝑛

(38)

𝑖=1

where the averaging is performed over the 𝑛 pairs of aligned atoms and 𝑑𝑖 is the
distance between the two atoms in each 𝑖 𝑡ℎ pair, presented in Å units. [201]
RMSD is calculated between the alpha carbon (𝐶𝛼 ) of paired equivalent atoms for
any subset (or all) residues between two proteins.
The key disadvantage when using RMSD is the magnitude by which it is swayed by
the amplitude of error. Two structures that are highly similar or identical with each other
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with the exception of a single region of difference (such as a disordered loop or terminus)
will have a very large RMSD and cannot accurately be superimposed. A pair of proteins
that only differ in one region will have a similar global backbone RMSD to that of a
protein pair with multiple small-scale differences throughout the entire structure. As s a
result, RMSD scores are strongly affected by both flexible and poorly defined regions.
[201]
RMSD scoring requires unambiguous establishment of atom pair correspondence
which is problematic when considering residues that possess internal symmetry or
multiple equivalent side chain rotamers. Typically, assignment of atom pair
correspondence is established trivially via sequence alignment. However, for Arg, Asp,
Glu, Leu, Phe, Tyr, and Val residues this is not possible because some atoms are
topologically equivalent due to sidechain internal symmetry. For example, the 𝐶𝛿1 and
𝐶𝛿2 atoms within a Phe residue are topologically equivalent and can thus be mapped into
𝐶𝛿1 and 𝐶𝛿2 atoms of the corresponding Phe residue in a paired structure in two different
possible combinations. As a result, enumeration for the optimal rotamer of these residues
is necessary when calculating RMSD. Finding the optimal rotamers can change pocket
RMSD by up to 0.5 Å but this additional step increases the algorithm time complexity.
[201]
Additionally, RMSD scoring is heavily dependent on protein length and size. TMscore measurements address this issue by normalizing the distances between
corresponding atom pairs via applying a distance scale. In the TM-score calculation, a
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target protein 𝐿𝑡𝑎𝑟𝑔𝑒𝑡 and an aligned protein 𝐿𝑎𝑙𝑖𝑔𝑛𝑒𝑑 are assigned a score based off the
normalized distance between the atoms such that:

1

𝑇𝑀𝑠𝑐𝑜𝑟𝑒 = max

𝐿𝑡𝑎𝑟𝑔𝑒𝑡
[

𝐿𝑎𝑙𝑖𝑔𝑛𝑒𝑑

1

∑
𝑖=1

2

(39)

𝐷𝑖
1+(
)
𝐷0 (𝐿𝑡𝑎𝑟𝑔𝑒𝑡 ) ]

RMSD and TM-scoring are the most common measures of structural similarity used
when constructing protein structural alignments. In contrast to sequence-based alignment
methods, three-dimensional structural alignments focus solely on the relative shape and
positional similarity of protein structures based on atomic coordinates, irrelevant of the
two-dimensional protein sequence. Closely aligned protein models indicate potential
functional relationships that may not be apparent from sequence comparison alone.
Structural alignment algorithms often agree with sequence alignments; however, many
protein families have high structural and topological similarity despite low sequence
overlap as protein structure is more robust to evolutionary changes as compared to
sequence. [201], [202] As an example, the ubiquitous TIM barrel motif is found in over
70 different protein families despite sequence variations. While sequence-based
techniques do not detect this similar motif accurately, structural alignments find
meaningful patterns allowing for recognition of the ubiquitous TIM barrel. [180], [192]
In comparison to the use of traditional multiple structural alignment metrics like
RMSD and TM-scoring, there is also evidence for success in the literature for using
machine learning-based feature selection of structural features. The literature
demonstrates the utility of GNM and ANM output features as determinants of
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“informative residue positions.” Following the generation of a multiple structure
alignment and feature generation of GNM and ANM fluctuations and residue depths,
features are aligned after discarding gap positions in the alignment. The data was fit using
a logistic regression model with Lasso regularization and the absolute value of the feature
coefficients at each position was used to determine feature importance. This method
resulted in an AUC-score of 0.98 ± 0.03 for a cyclin-dependent kinase classification
model. [192] This method serves as strong evidence for the applicability of physical
chemistry modeling and structural analysis to machine learning feature engineering.
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3. Methodology
3.1

Literature search and model selection

A literature search was conducted for journal articles in the NCBI PubMed database
within the previous five years containing any or all of the following terms: “neural
network”, “deep learning”, “machine learning”, “prediction” + “protein binding”,
“receptor”, “ligand binding”, “drug binding”, “protein-ligand interaction”, “drug-target
interaction”. Results were filtered based on classifier output to obtain published
architectures where the output predicts interaction activity between a protein and a ligand
binding partner (i.e., as compared to prediction of binding site location, free energy, et
cetera). Out of 293 total results, four papers were selected for comparison based on
superior performance metrics. The selected papers describe architectures referred to as
DeepConv, SSNet, DeepScreen, and DeepAtom, respectively. [19]–[22] While each
model is reported to have high accuracies, weaknesses in their general applicability as
indicated by strict data input requirements, large dataset necessity, and inconsistent
results against varying test datasets still demonstrate a gap in the literature for
improvement. Table 2 summarizes the architecture, requirements, strengths, and
weaknesses of each model.
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Table 2. Comparison of Selected Protein-Ligand Interaction Deep Learning Models. DeepConv, SSNet, DeepScreen, and DeepAtom
models are summarized for its implementation strategy, performance and model strengths, and model weaknesses.
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3.2

Data collection and cleaning

Benchmark test data for Specific Aim One were adapted from the Database of
Useful Decoys – Enhanced (DUD-E). [25] Each selected model requires different input
formats, including ChEMBL entries, sequence data, apoprotein structure, and proteinligand complex data. The original complete DUD-E dataset was filtered for interactions
that contain all of these available data, resulting in 438 interactions spanning 11 protein
receptors. This dataset was relatively class balanced with approximately 56% of data
observations belonging to the positive class. In addition to the benchmark test set, a small
test set of Subgroup A17 (serotonin and dopamine) receptors was generated containing
37 interactions spanning 4 protein receptors.
To correct a strong class imbalance in the Subgroup A17 data (70.2% of data
observations belonging to the positive class), the negative class was oversampled using
SMOTE (see 3.3) resulting in an equally balanced dataset. [203] The newly generated
dataset with added synthetic datapoints contains 52 observations split between 26
positive and 26 negative interactions.
Specific Aim Two and Specific Aim Three datasets were adapted from the Protein
Databank (PDB) [204], G Protein-Coupled Receptor Database (GPCRdb) [205][206],
Psychoactive Drug Screening Program (PDSP) [26], and DrugBank [207] to obtain
thorough, experimentally validated interaction data for Subgroup A17 positive and
negative interaction behavior wherein ‘positive interactions’ refer to a drug-target pair
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associated with a measured Kd / Ki < 10,000nM and ‘negative interactions’ refer to a
drug-target pair associated with a measured Kd / Ki ≥ 10,000nM per previously published
protocols in the literature.
For Specific Aim Two, a small dataset of Group A GPCR protein structures was
collected to test the effect of structure-based feature selection methods on accuracy and
time complexity of classification methods. Initially, 35 PDB structures of Group A
proteins were collected based on exclusion criteria selecting for high resolution, high
percent sequence coverage, active conformation apostructures. These 35 structures
spanned ten different Group A subgroups, six of which contained less than two structures
per subgroup. Proteins belonging to these smaller groups were removed to ensure quality
classification input. The remaining subset of proteins included 29 proteins spanning six
subgroups (A4, A12, A13, A15, A16, A18). Each protein is associated with a data tensor
containing structural data from the PDB file including .xyz coordinate data, secondary
structure information, and bond angles. This structural data was used to generate an
anisotropic network model for each protein with a cutoff of 15A for alpha carbon
interactions calculating 20 normal modes per protein structure (see 3.4).
Eigendecomposition was computed using MATLAB. [208]
Alpha carbon fluctuations from each ANM model respectively were aligned using a
multiple sequence alignment from the Caretta algorithm. [192] In total, 298 residues were
aligned and following the removal of any positions with gaps, 174 positions
corresponding to 174 total features remained comprising the fully comprehensive feature
set. The dataset was imbalanced with a majority of the sample belonging to subgroup
A18 therefore SMOTE was applied to the dataset. The final dataset contained 78
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observations. Additionally, a limited feature set for these observations was subsetted
based on the 25 residue positions with the largest magnitude variance values (15% of the
original feature set) to test the hypothesis that structure-based feature selection methods
are capable of reducing model training time without sacrificing model accuracy.
To determine the potential for learning pharmacodynamic behavior patterns from
structural GPCR data, two datasets were generated containing pairs of either serotonin (5HT) or dopamine (DRD) receptors respectively and corresponding ligands labeled for
each receptor as an interacting pair (also referred to as a ‘positive’ or ‘active’ interaction
or coded with an output of ‘1’) or a non-interacting pair (also referred to as a ‘negative’
or ‘inactive’ interaction or coded with an output of ‘0’). Data was obtained from the
GPCRdb, PDSP databases, and the DrugBank for GPCR structure, interaction data and
psychoactive drug activities. [26], [205]–[207]
5-HT receptor data was joined from the three online databases using SQL to
generate a single united dataset. Each database contains experimental values for the 5HT1a, 5-HT1b, 5-HT2a, 5-HT2b, and 5-HT2c receptor isoform drug-target interactions.
Additionally, PDSP and DrugBank contain additional experimental values for confirmed
non-interacting ligands to obtain validated negative interaction examples. SQL join
functions were used to filter each database for serotonin assay results, simultaneously
removing irrelevant proteins and redundant data entries. A number of drug-target pair
assay results were found to be duplicates with contradictory reported results, which is to
be expected with differing conditions and assay kits within experimental research.
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To address this dilemma objectively, the decision to include a drug-target pair was
based on the agreement of results in reference to the 10,000nM decision boundary to
discern between positive/negative interactions to reflect the boundary given in previously
published models. [19-22] If each duplicate assay entry lies on the same side of the
boundary, results are combined into a single observation based on the resulting binary
output encoding. On the contrary, if duplicate assay results span a range included, but not
bound by, 10,000nM, these results are contradictory and all results for the given drugtarget pair are thrown out (e.g., if a given 5-HT receptor has three listed assay results with
one result under 10,000nM and two results above 10,000nM, these results are
contradictory; however, if one result equals 10,000nM and two results are above 10,000,
these results are considered to be in agreement and will be combined into a single data
observation encoded as ‘0’). In addition to addressing duplicate results, data was also
cleaned for duplicate ligand entries under varying chemical names, null values, and
incomplete entries. Although the 10,000nM boundary does not appropriately represent
the biochemical significance of binding strength (e.g., the difference between a
dissociation constant of 1nM and 900nM leads to a substantially different biochemical
effect), it was not possible to accurately and objectively predict a continuous output
variable of dissociation constants due to duplicate and contradictory results in the
literature for certain binding interactions as described above. Clinically relevant examples
of GPCR binding interactions run the gamut of binding affinities and multiple arguments
could be made for various threshold boundaries to be of pharmacological importance.
The scale of binding affinities of drugs is often much lower than the binding affinities of
native ligands and could arguably deserve different threshold values. We should also
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ideally consider factors such as transient binders, allosteric binders, and receptor
mutations.
Because of our limitations with the number of variables to account for, training data
required, maintenance of data quality, and factors involved in binding threshold
determination, we chose to opt for a binary classification and use the same decision
boundary as other models. Using the same decision threshold is also valuable when
comparing model accuracies. Other ways that this could be handled other than the added
complexity described above include a multiclass model where we have more decision
boundaries to more specifically categorize binding interaction strength. The final clean 5HT dataset contains 36,208 interactions with approximately 57% negative and 43%
positive interactions.
Each protein is associated with a data tensor containing structural data from the PDB
file including .xyz coordinate data, secondary structure information, and bond angles.
This structural information was used to generate ANM for each 5-HT model as
previously described for Specific Aim Two dataset creation methodology.
In total, 342 residues were aligned and following the removal of any positions with
gaps, 282 positions corresponding to 282 total features remained comprising the fully
comprehensive feature set. SMOTE was applied to the positive class to fix imbalance as
this adjustment improved overall model accuracy. Additionally, ligand binding partners
associated with a SMILES identifier for chemical structure were described by features
extracted by the RDKit feature engineering program for a total of 201 features describing
physiochemical, quantum, and topological descriptors of each molecule. ([209],
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Appendix A) The final 5-HT dataset contained 42,656 observations consisting of twodimensional vectors encoding 483 features describing protein and ligand structure.
Additionally, a limited feature set for these observations was subsetted based on the 42
residue positions with the largest magnitude variance values (15% of the original feature
set) based on evidence supporting the hypothesis from Specific Aim Two.
DRD data was collected, joined, and cleaned using an identical protocol to that of
the 5-HT dataset. As a result, a dataset containing drug-target interactions classified by a
binary positive/negative output value was generated for the DRD1, DRD2, DRD3, and
DRD4 isoforms. DRD5 was excluded due to the lack of a high-resolution solved
structure. Structural feature tensors were generated from PDB files as input for the ANM,
and feature engineering from ANM results was conducted as previously described for the
5-HT isoforms. In total, 369 residues were aligned and following the removal of any
positions with gaps, 302 positions corresponding to 302 total features remained
comprising the fully comprehensive feature set. Synthetic Minority Oversampling
Technique was applied to the positive class to fix imbalance as this adjustment improved
overall model accuracy (see 3.3) . Ligand binding partners were described by 201 RDkit
features as previously described. The final DRD dataset contained 2,063 observations
consisting of two-dimensional vectors encoding 503 features describing protein and
ligand structure. Additionally, a limited feature set for these observations was subsetted
based on the 75 residue positions with the largest magnitude variance values (15% of the
original feature set) based on evidence supporting the hypothesis from Specific Aim
Two. All programing methodology is further detailed in Appendix B.
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3.3

Synthetic datapoint generation

For all datasets, Synthetic Minority Oversampling Technique (SMOTE) was used to
generate synthetic datapoints oversampling the minority class to achieve a more balanced
dataset. [203] Briefly, SMOTE selects random datapoints from the underrepresented class
and determines the n-nearest neighbors of a given datapoint. New data points are
generated by selecting a random point on the vector that connects the original datapoint
and a selected ni neighbor. This process is repeated until the dataset is equally distributed.
SMOTE was implemented using the imbalanced-learn module. SMOTE is a wellestablished, robust method with approximately two decades of published success in the
literature. [210]
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3.4

Anisotropic network model

ANMs can predict anisotropic motions of atoms via computation on the force
constant matrix (𝑯) containing data describing the orientation of each interaction with
respect to the global coordinates where:

𝑯= [

𝐻𝑖𝑖
𝐻𝑗𝑖

𝐻𝑖𝑗
]
𝐻𝑗𝑗

(40)

where 𝑖 and 𝑗 are nodes in the model representing two 𝐶𝛼 in the protein and each
element 𝐻𝑖𝑗 in the matrix represents the anisotropic information regarding the orientation
of nodes 𝑖 and 𝑗. [184], [185] The Hessian matrix 𝑯 describing the force constant of the
system is equivalent of the second partial derivative of the harmonic potential 𝑉𝑖,𝑗 defined
as:
𝑉𝑖,𝑗 =

𝛾
𝑜 2
(𝑠𝑖,𝑗 − 𝑠𝑖,𝑗
)
2

(41)

where 𝛾 represents the unknown spring constant, 𝑠𝑖,𝑗 is the instantaneous distance
𝑜
between 𝑖 and 𝑗, and 𝑠𝑖,𝑗
is the equilibrium distance between 𝑖 and 𝑗. Therefore:

𝜕 2 𝑉𝑖,𝑗 𝜕 2 𝑉𝑖,𝑗
𝛾
2
=
=
2
2
2 (𝑥𝑗 − 𝑥𝑖 )
𝜕𝑥𝑖
𝜕𝑥𝑗
𝑠𝑖,𝑗

(42)

𝜕 2 𝑉𝑖,𝑗
−𝛾
= 2 (𝑥𝑗 − 𝑥𝑖 )(𝑦𝑗 − 𝑦𝑖 )
𝜕𝑥𝑖 𝜕𝑦𝑖 𝑠𝑖,𝑗

(43)
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where the instantaneous positions of atoms 𝑖 and 𝑗 are defined by their respective
coordinates (𝑥𝑖 , 𝑦𝑖 , 𝑧𝑖 ) and (𝑥𝑗 , 𝑦𝑗 , 𝑧𝑗 ). As a result, 𝑯 can be expanded as:
𝜕 2 𝑉𝑖,𝑗
𝜕𝑥𝑖 𝜕𝑥𝑗
𝜕 2 𝑉𝑖,𝑗
𝑯=
𝜕𝑦𝑖 𝜕𝑥𝑗
𝜕 2 𝑉𝑖,𝑗
[ 𝜕𝑧𝑖 𝜕𝑥𝑗
(𝑥𝑗 − 𝑥𝑖 )(𝑥𝑗 − 𝑥𝑖 )
−𝛾
= 2 [(𝑦𝑗 − 𝑦𝑖 )(𝑥𝑗 − 𝑥𝑖 )
𝑠𝑖,𝑗
(𝑧𝑗 − 𝑧𝑖 )(𝑥𝑗 − 𝑥𝑖 )

𝜕 2 𝑉𝑖,𝑗
𝜕𝑥𝑖 𝜕𝑦𝑗
𝜕 2 𝑉𝑖,𝑗
𝜕𝑦𝑖 𝜕𝑦𝑗
𝜕 2 𝑉𝑖,𝑗
𝜕𝑧𝑖 𝜕𝑦𝑗

𝜕 2 𝑉𝑖,𝑗
𝜕𝑥𝑖 𝜕𝑧𝑗
𝜕 2 𝑉𝑖,𝑗
𝜕𝑦𝑖 𝜕𝑧𝑗
𝜕 2 𝑉𝑖,𝑗
𝜕𝑧𝑖 𝜕𝑧𝑗 ]

(44)

(𝑥𝑗 − 𝑥𝑖 )(𝑦𝑗 − 𝑦𝑖 )

(𝑥𝑗 − 𝑥𝑖 )(𝑧𝑗 − 𝑧𝑖 )

(𝑦𝑗 − 𝑦𝑖 )(𝑦𝑗 − 𝑦𝑖 )

(𝑦𝑗 − 𝑦𝑖 )(𝑧𝑗 − 𝑧𝑖 )]

(𝑧𝑗 − 𝑧𝑖 )(𝑦𝑗 − 𝑦𝑖 )

(𝑧𝑗 − 𝑧𝑖 )(𝑧𝑗 − 𝑧𝑖 )

𝑥 − 𝑥𝑖
−𝛾 𝑗
= 2 [𝑦𝑗 − 𝑦𝑖 ] [𝑦𝑗 − 𝑦𝑖
𝑠𝑖,𝑗 𝑧𝑗 − 𝑧𝑖

𝑦𝑗 − 𝑦𝑖

𝑧𝑗 − 𝑧𝑖 ]

(45)

(46)

While the matrix 𝑯 is not invertible, a pseudoinverse can be obtained via 𝑯 =
𝑼Λ𝑼𝑇 to obtain the eigenvectors and nonzero eigenvalues. The eigenvalues describe the
vibrational direction and amplitude in the different modes. The mean square fluctuations
of specific residues can be obtained by summing the fluctuations in each individual
mode, i.e.,
〈𝚫𝑹𝟐𝒊 〉 = 〈Δ𝑋𝑖2 〉 + 〈Δ𝑌𝑖2 〉 + 〈Δ𝑍𝑖2 〉 =

𝑘𝐵 𝑇 −1
−1
−1
̃3𝑖−2,3𝑖−2 + 𝐻
̃3𝑖−1,3𝑖−1
̃3𝑖,3𝑖
[𝐻
+𝐻
]
𝛾

(47)

Additionally, the cross correlation between different residues can be calculated via:
〈Δ𝑅𝑖 ⋅ Δ𝑅𝑗 〉 = 〈Δ𝑋𝑖 ⋅ Δ𝑋𝑗 〉 + 〈Δ𝑌𝑖 ⋅ Δ𝑌𝑗 〉 + 〈Δ𝑍𝑖 ⋅ Δ𝑍𝑗 〉
=

𝑘𝐵 𝑇 −1
−1
−1
̃3𝑖−2,3𝑗−2 + 𝐻
̃3𝑖−1,3𝑗−1
̃3𝑖,3𝑗
[𝐻
+𝐻
]
𝛾
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(48)

Anisotropic network models were generated for each protein with a cutoff of 15Å
for alpha carbon interactions calculating 20 normal modes per protein structure.
Eigendecomposition was computed to determine the mean square fluctuations of alpha
carbons, elastic potential energy and B-factors using the DSSP module in MATLAB as
previously published. [211] Fluctuation data was used to generate machine learning
features while fluctuations, elastic potential energy, and B-factors were all factored into
molecular modeling and simulation analysis. All model visualization, movie trajectories,
and image rendering were completed in Jmol. [212] All programing methodology is
further detailed in Appendix B.
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3.5

Structural analysis using molecular modeling and simulation

All protein and ligand structural data was obtained from the PDB. [204] Receptors
lacking solved structure data were omitted from all datasets and analyses. All structural
analysis was completed in the UCSF Chimera 1.11.2 program. [213] Atomic contacts and
hydrogen bonding prediction were completed post-structure steepest descent
minimization and solvation in a TIP4P-Ew model. Solvation models are crucial to
calculation accuracy as solvation energies and intermolecular interactions between
solvents and solvated molecules will affect all other interaction calculations. [82]The
TIP4P-Ew model is a re-parameterization of the TIP4P model using Ewald techniques.
The TIP4P water solvation model is a rigid planar four-site interaction potential for water
consisting of a Lennard-Jones site for the oxygen atom and three charge sides with a
‘mock’ atom maintaining molecule geometry and force distribution. [214] The TIP4P
model is summarized in Table 3.

Table 3. TIP4P Model Parameters. The TIP4P model is described above in terms of bond angles and radii,
dielectric constant, and charge. TIP4P contains a Lennard-Jones site for the oxygen atom where ε describes
the well depth and σ is the value of r at which the Lennard-Jones potential equals zero.
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When adjusted for the Ewald sum technique to better simulate electrostatic
interactions within a system via the introduction of charge “clouds”, the model is adjusted
to values as described in Table 4. A visualization of the TIP4P-Ew model is given in
Figure 14.

Table 4. TIP4P-Ew Model Parameters. The TIP4P-Ew model is described above in terms of bond angles
and radii, dielectric constant, and charge. TIP4P-Ew contains a Lennard-Jones site for the oxygen atom
where ε describes the well depth and σ is the value of r at which the Lennard-Jones potential equals zero. In
contrast to TIP4P, the TIP4P-Ew is reparameterized to include the Ewald sum technique, improving the
simulation of long range electrostatic interactions.

Figure 14. Representation of the molecular model of water used in the TIP4P-EW solvation model. A
‘mock atom’ is placed in between the hydrogen atoms to maintain model geometry where rOH and rOM are
the bond lengths between the oxygen and hydrogen and mock atoms, respectively and HOH* refers to the
bond angle of the molecule.

Following structure minimization and solvation, atomic contacts and hydrogen
bonds are predicted based on the theoretical calculation of the overlap between two given
atoms for all atomic pairs in a given protein receptor where overlap is defined as:
𝑜𝑣𝑒𝑟𝑙𝑎𝑝𝑖𝑗 = 𝑟𝑉𝐷𝑊𝑖 + 𝑟𝑉𝐷𝑊𝑗 − 𝑑𝑖𝑗 − 𝑎𝑙𝑙𝑜𝑤𝑎𝑛𝑐𝑒𝑖𝑗

(49)

where allowance refers to a correction for potentially hydrogen-bonded pairs in
which an allowance > 0 reflects the observation that atoms sharing a hydrogen bond can
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have a shorter atomic distance than would be predicted from their van der Waals radii.
Allowances are only taken into account for pairs containing a hydrogen donor and an
acceptor. Atomic contacts are determined via a cutoff value of -0.4 Å and an allowance
value of 0.1 Å. Pairs that are >3 bonds apart are ignored. Using a similar protocol
combined with previously published methodology [215], hydrogen bonding pairs are
predicted. All models are visualized and images generated using the built-in rendering
tools of Chimera 1.11.2. All programing methodology is further detailed in Appendix B.
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3.6

Logistic regression model parameters

Logistic regression models were built using the scikit-learn class within the
linear_model module. (Appendix B, [115]) Table 5 describes the chosen hyperparameter
values. Omitted parameters were set to the default values. The SAGA solver is a variant
of the Stochastic Average Gradient (SAG) method which optimizes the sum of a finite
number of smooth convex functions. SAG converges much faster than other stochastic
gradient methods as its iterative cost is independent of the number of function terms in
the calculated sum. While it is faster than other solvers, it can be impractical for large n
due to its memory cost. The SAGA variant differs in that it also supports non-smooth
regularization options, making it a more ideal choice for sparse and/or very large
datasets. The scikit-learn documentation recommends the SAGA solver as the best choice
in most cases despite limited-memory Broyden-Fletcher-Goldfarb-Shanno (LBFGS)
being the default option. [115]

Table 5. Logistic Regression Model Hyperparameters. Optimized hyperparameters for all logistic
regression models. Omitted hyperparameters were not adjusted from default values.
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3.7

Decision tree-based model parameters

Decision-tree based classifiers including random forest, extra trees, and bagging
decision tree models were constructed using the scikit-learn ensemble module.
(Appendix B, [115]) The extra trees classifier compares to a random forest classifier in
that they each build multiple decision trees in which nodes are split using random subsets
of features. The two algorithms contrast in that extra trees classifiers do not bootstrap
observations and nodes are split randomly rather than on best splits. Bagging trees differs
from random forest in that all features are taken into account when splitting a node rather
than randomly selecting a subset of features. Optimized hyperparameters for each method
are summarized in Table 6. Omitted parameters were set to default values.

Table 6. Decision Tree-Based Model Hyperparameters. Optimized hyperparameters for all decision treebased models, including random forest, extra trees, and bagging trees classifiers. Omitted hyperparameters
were not adjusted from default values.
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3.8

Support vector machine model parameters

Support vector classifiers were built using the scikit-learn ensemble module.
(Appendix B, [115]) Table 7 describes the optimized hyperparameter set used. A
polynomial kernel was selected over the more common radial basis function (RBF) due
to its increased computation speed without sacrificing performance (data not shown).

Table 7. Support Vector Machine Model Hyperparameters. Optimized hyperparameters for all SVM
models. Omitted hyperparameters were not adjusted from default values.
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3.9

AdaBoost model parameters

AdaBoost classifiers were built using the scikit-learn ensemble module. (Appendix
B, [115]) Default parameters were found to result in the optimized model and can be
found in the sklearn documentation.
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3.10

Performance metrics and cross validation methods

All model performance is measured by a combination of precision, recall, confusion
matrices, F1-scoring, and ROC AUC scores as described in Chapter One.
Each test set performance is measured by a 10-fold cross-validated F1 score
implemented via the scikit-learn metrics module. (Appendix B, [115]) In K-Fold Cross
Validation, data is randomly shuffled and split into k numbers of folds (i.e., groupings of
data). One fold is separated into the test dataset, while the other k-1 folds are grouped
together into the training data. The model is fitted and evaluated via a chosen
performance metric score. The process repeats iteratively with each fold as the test data
and the final k scores are averaged to form a more robust model validation score. F1scoring was chosen as the performance metric due to the binary nature of the models as
well as the consequence of positive class errors. [216]
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3.11

Deep neural network model parameters and architecture

Models were replicated using publicly available code from GitHub repositories
provided by authors. All models were replicated and tested in either a GPU-enabled
Python 3 environment using JupyterLab or within the SageMaker service from Amazon
Web Services (AWS).
A deep feedforward neural network was built within the PyTorch framework. [217]
Despite experimentation with more complex architectures, it was found that a
feedforward architecture was sufficient to achieve high accuracy and ideal over other
methods due to its computational speed. The model architecture, summarized in Figure
15, is composed of five linear layers with batch normalization following each layer and
dropout layers following the first and last hidden layers. Batch normalization was
implemented to increase model speed and stabilize each layer’s input via restandardization of the data whereas dropout layers were implemented to prevent
overfitting. [139], [169] Placement of batch normalization and dropout was guided by
previously published architectures. [21], [133], [169] Model implementation with the
Exponential Linear Unit (ELU) activation function was found to result in better
performance than other activation functions. ELU activation is more computationally
expensive than the popular Rectified Linear Unit (ReLU) activation function, but in
addition to avoiding the vanishing gradient problem, it also avoids the dead ReLU
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problem. Loss is measured by the binary cross entropy criterion. Performance metrics
include cross validated F1-score, precision, recall, and ROC AUC score.

Figure 15. Architecture of feedforward, fully-connected deep neural network used for drug-target
interaction prediction of Subgroup A17 receptors. A model with five hidden layers (each followed by
batch normalization and a dropout layer following the first and fifth hidden layers (p=0.2 and p=0.7
respectively) was found to result in the best performance.
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4. Results and Discussion

4.1

Specific Aim 1. To test the performance of current machine learning

algorithms for the classification of protein binding behavior and determine the
extent to which these architectures can be applied to the classification of Class A
GPCR-drug interactions.
4.1.1

Current state-of-the-art method performance against a DUD-E

benchmark dataset
To validate the replicability of the selected prior published protein-ligand interaction
neural network classifiers (DeepConv [21], SSNet [22], DeepScreen [20], and DeepAtom
[19]), trained models were built from publicly available code provided by the authors in
each model’s respective framework as written. Each publication uses different
performance metrics; however, for consistency in our analysis we chose to measure
accuracy via the F1-score metric. While this makes direct comparison to published results
less interpretable, generalized conclusions on model accuracy are still possible. Multiple,
but not all, of the models selected the DUD-E database as a validation set but all models
were tested on a generalized protein-ligand database containing a wide breadth of protein
families and ligand classes, therefore the DUD-E database is a suitable test set for all four
models. A 10-fold cross validated F1-score (± standard error) for each model is given in
Figure 16.
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DeepConv reports an AUC score of 0.852 [21] against a dataset constructed from a
mixture of drug-target interaction databases (e.g., KinaseSAFARI, PubChem, DrugBank)
while our model obtained a cross-validated F1-score of 0.764 ± 0.028. (Figure 16) It is of
note that our DUD-E test set was considerably smaller than the test set from published
results (438 interactions vs. >36,000 interactions) which potentially influenced results.
DeepScreen reports an F1-score of 0.87 [20] against a large dataset of
experimentally-validated protein-ligand interactions, and our replicated model results
were in strong agreement with these published results. The replicated pre-trained model
resulted in a cross-validated F1-score of 0.88±0.016 against the DUD-E test set. (Figure
16)
DeepAtom reports a Pearson correlation of 0.83 [19] against a dataset of PDBind
protein-ligand complexes. When the DUD-E test set was applied to the replicated pretrained model, an F1-score of 0.805±0.0304 was obtained. (Figure 16)
SSNet reports an AUC of 0.93 [22] against a dataset containing protein-ligand
interaction data from DUD-E with Kd values greater than 10,000nM or smaller than
100nM. When applied to our broader range of DUD-E test data, the model resulted in a
cross-validated F1-score of 0.81±0.075. (Figure 16)
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Figure 16. Protein-ligand interaction classifiers perform significantly worse than reported accuracy metrics on a test
set containing Subgroup A17 GPCRs. Model performance of four previously published architectures against a benchmark
test set adapted from the DUD-E interaction dataset and a test set consisting of drug-target interactions from the Class A
Subgroup A17 of proteins including dopamine and serotonin receptors. Accuracy was measured by a 10-fold cross validated
F1-score. Each replicated model performed significantly worse against the Subgroup A17 dataset than the DUD-E dataset.
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4.1.2

Current state-of-the-art method performance against a GPCR

Subgroup A17 test set
Despite the potential concern associated with the DeepConv author’s dataset creation
methodology, the accuracy of this model was still comparable to published metrics when
tested against the experimentally validated DUD-E dataset. However, once applied to a
specific protein family test set, model accuracy significantly dropped (p<0.05). This
additional test set contained experimentally validated data for proteins within the GPCR
Subgroup A17 (serotonin and dopamine receptors) and resulted in in an average crossvalidated F1-score of 0.685 ± 0.05, both a lower accuracy and higher standard error rate
than that of the more general DUD-E dataset. (Figure 16)
While accuracy did significantly drop for the Subgroup A17 test as compared to the
DUD-E test set (p<0.05), the model against the Subgroup A17 data still obtained a crossvalidated F1-score of 0.71±0.028. (Figure 16)
The DeepAtom framework performed well against the general DUD-E dataset but
did not demonstrate any predictive ability against the Subgroup A17 dataset, as
evidenced by the cross-validated F1-score of 0.462±0.043. This data suggests that the
structural features extracted from the serotonin and dopamine receptor complexes via the
DeepAtom algorithm are not useful for interaction prediction. (Figure 16)
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SSNet performed significantly worse against the Subgroup A17 dataset than the
general DUD-E test set (p<0.05) with a comparably large standard error (cross-validated
F1-score of 0.62±0.088). (Figure 16)

86

4.1.3 Discussion of current published models and potential applicability to
Subgroup A17 proteins
While we hypothesized that training on a broader, more general dataset of proteinligand interactions would result in a higher test accuracy for a specific protein group due
to similar overarching physiochemical properties that determine protein binding behavior
and a larger volume of available training data, this was not observed for any of the
replicated classifiers. It is possible that while the available amount of data for generalized
protein-ligand interactions is larger, the conformational dynamics governing ligand
binding behavior is too different between groups with drastically different structure to
simplify structure-function relationship for ligand binding across multiple protein
families. This data suggests that the potential for transfer learning within protein-ligand
binding is lower than expected.
A strength of DeepConv, as stated by the authors, is the generable applicability of
the model due to the model only requiring sequence data and no structural information.
[21] However, this data suggests that despite not using three-dimensional structures, the
applicability of this model is limited. It is also of note that while the DeepConv model
does not require structure information, the input format requires available ChEMBL data.
While this program feature was likely introduced to improve user experience, it does
limit the data compatibility range of the model.
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The Subgroup A17 dataset contained 52 observations and it is possible that the small
dataset size influenced model accuracy. It is a noted limitation of this aim that finding
data to satisfy the input requirements of all four models significantly reduced the
availability of usable data. While it is possible to modify these models to allow different
input structures or re-train the model using our datasets, the amount of work necessary to
complete these tasks would be overambitious and beyond the scope of this project.
The DeepScreen authors’ data collection strategy for both training and testing data is
an additional factor that may address disparities between the published accuracy of
DeepScreen and accuracy against other datasets. [20] For the datasets tested in this work,
we chose to only include experimentally validated negative interactions. Additionally,
test data were randomly generated from the full dataset using the train_test_split function
from the scikit-learn model_selection module. [115]
In contrast, the data used to train and test DeepScreen by the authors contained
experimentally validated positives and randomly generated ‘scrambled’ negative data
(i.e., positive interaction pairs were randomly shuffled to generate a new set of theoretical
interaction pairs and any overlapping samples between the original and shuffled dataset
are removed to generate a novel dataset containing new interactions which will be labeled
as negatives). These interactions were not compared to published experimental data. As
the dataset was pulled from a small subset of the publicly available protein-ligand
interaction data, it is very likely that a large number of experimentally-validated positive
interactions were not included in the data and therefore it is also possible that some of the
scramble-generated ‘negative’ interactions have been experimentally validated as
positive, or not yet tested to confirm either way. Moreover, the data chosen to be
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scrambled by the researchers was hand-selected and chosen by protein family rather than
a random distribution of all data. As a result, researcher bias may have been introduced
into the dataset. It is possible that rather than predicting drug interaction probabilities, the
program was identifying real vs. randomized data observations.
Overall, the DeepScreen model outperformed other models against both test sets.
However, a significant drawback to this model is the requirement of detailed structural
information for each interaction. DeepScreen utilizes a three-dimensional apoprotein
structure, a ligand structure, and a protein-ligand complex. While the authors were able to
compile a large training dataset by including a broad range of proteins from multiple data
sources and multiple protein families, this model has limited applicability as solved
protein structures are rare and solved protein-ligand complex structures are even more
rare. Additionally, the complexity and high dimensionality of this data results in
extremely high model complexity and long training times. As a result, despite the strong
evidence that DeepScreen displays for the use of structural information in protein-ligand
interaction classification, the field of structure-oriented machine learning research still
lacks real-world feasibility in terms of general applicability.
The DeepAtom model demonstrates reasonable performance against a general
protein-ligand interaction dataset but does not perform well against a test set of familyspecific interactions. [19] The DeepAtom model is arguably one of the most complex
predictive models published for protein-ligand interaction prediction currently available.
Three-dimensional protein-ligand complex structures are voxelized with channels
containing encoded feature information describing atoms within each respective voxel.
The voxelized structure undergoes a three-dimensional convolution to predict an
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inhibition constant value. Despite the complexity of the model structure, only 24 features
are used to describe the entire complex and the results of our analysis suggest that these
24 features are not generally applicable to all protein-ligand interaction datasets.
SSNet resulted in a comparable average F1-score for the DUD-E data set and the
Subgroup A17 data set to the other three tested models. [22] The standard error for this
model was considerably higher than other models and unusually high for a crossvalidated classifier performance, suggesting that a certain amount of randomness is
contributing to the model prediction. In addition to the concern provided by this large
standard error repeated across multiple experiments (data not shown), the model was only
trained to handle extreme values for positive interactions. It is possible that the model
does not predict well for positive interactions with Kd values above 100nM as the
training data only classified interactions with dissociation constants below this threshold.
As an example, the D2 receptor has a reported affinity for dopamine ranging between
~400-700nM. [26] Under the classification threshold criteria for SSNet, dopamine would
not be considered a positive ligand for D2. The lack of consistency and range of ligand
input of the SSNet predictive ability raises concern about the model’s potential for
applicability.
Overall, while each tested model demonstrated strengths to guide the development of
future models, each also raised concerns about classifier replicability and performance
generalizability. Each model performed relatively well compared to other published
classification models in the literature against the DUD-E adapted test set, but no models
transferred well to the Subgroup A17 dataset. These results not only demonstrate a need
for improved models to be developed, they also provide valuable information to guide
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future directions. Firstly, the poor performance against Subgroup A17 data suggests that
the hypothesis that general relationship patterns in protein-ligand binding can be
universally applied to more specific protein groups is false. Although it would be ideal to
be able to train on a larger, broader data set to maximize learning potential and
intermolecular interactions are generally governed by the same physical and chemical
principles, it appears that the biochemical conformational dynamics responsible for
ligand binding are too complex and unique within protein classes and subgroups to be
applied broadly. To determine feature importances for Subgroup A17, it would be
possible to iteratively freeze all model weights with one feature left out to better
characterize relationship between each feature and output accuracy.
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4.2

Specific Aim 2. To assess the degree with which model performance of

a Class A GPCR subgroup classifier can be maintained as we reduce time
complexity via structure-based feature selection.
4.2.1

Multiple structural alignment of Class A GPCRs

A dataset of 29 Class A GPCR protein structures from a range of subgroups was
collected and aligned using the Needleman-Wunsch algorithm within the Caretta
structural analysis program, based on the BLOSUM62 similarity matrix for the twenty
standard amino acids. [192], [218] After gaps in the alignment are omitted, 174 residues
are aligned. Only fully aligned residues are included in any comparative studies to avoid
handling of missing values. A model visualization of the superimposed structures is given
in Figure 17.
In addition to the multiple-subgroup Class A dataset, two additional alignments were
generated for the structural alignment of four serotonin receptors (Figure 18) and four
dopamine receptors (full visualization not shown; binding site alignment shown in
Figure 19). The alignment of serotonin receptors (5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C)
reflected currently published data demonstrating that residues within the N-terminal loop
and ECL3 regions are highly conserved between serotonin receptors. The alignment of
dopamine receptors (DRD1, DRD2, DRD3, DRD4) reflected currently published data
demonstrating that twelve out of thirteen key ligand-binding residues are highly
conserved between dopamine receptors. [5] For additional comparative structural
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analyses, all 37 Class A proteins (multiple-subgroup Class A dataset, serotonin receptors,
and dopamine receptors) were aligned to determine structurally-unique regions for the
serotonin and dopamine subgroup within the context of each other and the overall
structural landscape of Class A GPCRs.

Figure 17. Multiple structural alignment of Class A GPCR proteins. 29 proteins, each in different color, are randomly
positioned in three dimensional space (left) and aligned into one overlapping structure (right). Alignment was created using the
Needleman-Wunsch algorithm based on the BLOSUM62 similarity matrix. Following alignment and removal of gaps between
all proteins, 174 aligned residues remained.

Figure 18. Multiple structural alignment of serotonin receptors 5-HT1A (PDB 7E2X), 5-HT1B, (PDB 5V54) 5HT2A (PDB 6A94), and 5-HT2C (PDB 6DS0). Alignment was generated using the Needleman-Wunsch algorithm. High
structural similarity reflects previously published data demonstrating binding site similarity between Class A GPCRs,
reducing effectiveness of feature sets focused on binding site residues.
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Figure 19. Multiple structural alignment of the D2 (PDB 6VMS)/D3 (PDB 6CMU)/D4 (PDB 5WIV) receptors
focused on the binding site. Alignment was generated using the Needleman-Wunsch algorithm. High structural similarity
reflects previously published data demonstrating binding site similarity between Class A GPCRs, reducing effectiveness of
feature sets focused on binding site residues.
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4.2.2

Anisotropic network model analysis of Class A GPCR proteins

For all 29 proteins within the multiple-subgroup Class A dataset, all four serotonin
receptor structures, and all four dopamine receptor structures included in our analysis, an
anisotropic network model was created. As an example, the visualization of the
theoretical first normal mode of 5-HT1A is shown in Figure 20.
In addition to atomic fluctuations and elastic potential energies (spring forces), it is
also possible to calculate the B-factor (also referred to as the temperature factor) of each
residue from the ANM. The B-factor quantitates the uncertainty of each atom under the
assumption that uncertainty in atomic position increases with disorder in the protein
structure. B-factors are directly correlated with the degree to which the electron density
for a given atom is spread out. A high B-factor reflects a low empirical electron density
for the atom and vice versa for low B-factors. While B-factors can also be used to
describe model error from X-ray crystallography, within thermodynamics theory, the Bfactor represents the dynamic mobility of an atom. The B-factor is given by:
𝐵𝑖 = 8𝜋 2 𝑈𝑖2

(50)

where 𝑈𝑖2 is the mean square fluctuation for a given atom i and as U increases, the Bfactor increases proportionally. B-factor can be useful when analyzing the contribution
of a given residue to the overall conformational dynamics of a protein and
conformational dynamics have been demonstrated to play an important role in ligand
association and dissociation. [219], [220]
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Within the ANM analysis for included Class A GPCR proteins, solvent-accessible
regions demonstrated higher B-factors than membrane-embedded regions.
Using structural data from previously calculated multiple structural alignments in
combination with ANM fluctuations for the alpha carbon of each residue for each protein,
it is possible to compare atomic fluctuation data at each aligned residue position between
all Class A GPCR proteins included in this study. The variance at each aligned position
was calculated and residue positions were enumerated by magnitude of variance.

Figure 20. Visualization of 5-HT1A Anisotropic Network Model, normal mode 1 out of 20 normal modes generated.
Arrow vectors indicate theoretical direction and magnitude of atomic fluctuations for the specific represented mode. Model
color gradient represents B-factor where red corresponds to higher values and blue corresponds to lower values.
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4.2.3

Comparative structural analyses of Class A GPCR binding behavior

and discussion of potential evidence provided by ANM data
Following minimization and solvation of apoprotein receptors, specific residues
identified by previous published structural analysis or our ANM results were examined to
determine what extent the ANM provided novel information. For protein-ligand complex
structures, predicted intermolecular hydrogen bonding between receptor and ligand were
calculated for all potential donor/atom pairs via atomic contact modeling. Figure 21
shows the structure of rhodopsin with functionally-important residues identified by
published studies in blue, ANM-identified regions of high structural deviation (i.e.,
regions in which theoretical atomic fluctuation patterns differ strongly from other Class A
proteins) compared to other Class A GPCRs in red, and any overlapping residues
previously identified that were also identified as structurally unique by ANM in green.
Outside of a single residue, all residues highlighted by ANM were novel and not
identified by our literature analysis of rhodopsin structure and conformational dynamics.
ANM-identified residues of high structural deviation had a strong positive correlation
with reported B-factors from the original published X-ray crystallography data. [221]
This correlation provides additional evidence that the ANM-identified regions are likely
to be influential in rhodopsin conformational dynamics.
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Figure 21. Results from the rhodopsin ANM yield a different residue set than other structural analysis methods. Residues
colored in red are regions of high structural deviation identified by ANM analysis. Blue residues are previously identified regions
of functional importance. A single residue was identified by ANM analysis that had previously been identified as important by
other structural methods. ANM-identified residues highly correlate with X-ray crystallography-obtained residues associated with
high B-factor.

Figure 22 represents the binding site of 5-HT1A in complex with LSD, a potent
serotonin receptor agonist often recreationally consumed for its hallucinogenic effects.
[207] While none of the ANM-identified structurally unique residues of 5-HT1A are
predicted to directly interact with LSD, predictive modeling of hydrogen bonding does
suggest that two ANM identified residues within close proximity of TM6 form bonds
with the toggle switch Trp residue (W6.48) key to the cascade of conformational changes
throughout the entire GPCR that result from extracellular ligand binding. [5] Despite the
lack of a direct role in ligand binding, this data still suggests that ANM-identified
residues of importance are involved in 5-HT1A ligand binding conformational dynamics.
As a final representative case, Figure 23 displays the binding sites of the D2
receptor (a) and the 5-HT2A receptor (b) in complex with haloperidol, a high affinity
dopamine receptor antagonist (Ki ≈ 1.4nM for D2 receptor-haloperidol interaction [26]).
In the bound conformational state, the toggle switch Trp residue is not close enough to
the binding site for any hydrogen bonding with the ligand to be predicted. Within the
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literature, the behavior of the toggle switch is inconsistent between different receptors
within the Class A GPCRs. [222]

Figure 22. Serotonin receptor atomic fluctuation data identifies important residues outside of binding pocket as
evidenced by analysis of the 5-HT1A/LSD complex. Residues identified as possessing high structural deviation via ANM
analysis are colored in red. The LSD ligand molecule is represented in yellow and 5-HT1A residues that form bonds with
LSD are represented in green. While none of the ANM-identified residues directly interact with LSD, structure analysis
within the UCSF Chimera program predicted that hydrogen bonding does occur between two of these residues and a key Trp
residue (W6.48; green, circled) for ligand bonding.

While some receptors demonstrate a large conformational change in the W6.48
residue upon ligand binding (formerly believed to be a universal mechanistic change in
all Class A GPCR activation), others do not display any significant W6.48 movement.
[223] Numerous other toggle switch-based and steric movement-based mechanisms have
been identified for various Class A GPCRs. Dopamine receptors have been identified to
undergo a W6.48-mediated conformational change upon ligand binding, while serotonin
receptors have been demonstrated to undergo a combination of a Tyr toggle switch- and
steric hindrance-based mechanism. [222] Moreover, it has been demonstrated that for the
5-HT1B receptor, W6.48 is actually directly involved in ligand binding. [224] While
ANM-identified residues within the D2-receptor are not predicted to form any hydrogen
bonds with W6.48, two residues within the 5-HT2A receptor are predicted to bond with
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W6.48 (as demonstrated for 5-HT1A in Figure 22). These hydrogen bonds may
potentially influence the conformational dynamics of ligand-mediated Class A GPCR
activation via their structural influence on W6.48 toggle location and ligand binding
potential.

Figure 23. Regions identified as important by ANM analysis highly influence haloperidol binding in psychoactive drug
receptors. A D2 receptor binding site in complex with haloperidol (yellow). In the bound conformational state, the toggle
switch Trp residue (W6.48) is not close enough to the binding site for any hydrogen bonding with the ligand to be predicted.
The D2 receptor/haloperidol complex (Ki ≈ 1.4 nM) is predicted to form ten intermolecular hydrogen bonds. Green residues
have previously been identified to participate in ligand binding. Red residues have been identified as structurally unique as
compared to other Class A GPCRs by ANM and are not predicted to form hydrogen bonds with the toggle switch. B 5-HT2A
receptor binding site in complex with haloperidol (yellow). In the bound conformational state, the toggle switch Trp is within
the binding site and predicted to be actively involved in ligand binding as previously demonstrated with other ligands. The 5HT2A receptor/haloperidol complex (Ki ≈ 47 nM) is predicted to form four intermolecular hydrogen bonds. Green residues
have previously been identified to participate in ligand bonding. Red residues have been identified as structurally unique as
compared to other Class A GPCRs by ANM, including two residues predicted to form hydrogen bonds with the toggle switch
(Figure 19), pulling it into the binding site.
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4.2.4

Influence of structure-based feature selection as determined by ANM

on the accuracy and associated time-cost of Class A subgroup classifiers
In addition to the utility of augmented structural modeling analysis with ANM, the
literature has also previously demonstrated potential for improved machine learning
feature engineering based on normal mode analysis methods including ANM. [192] To
test this hypothesis, data generated from multiple structural alignment and ANM of Class
A GPCRs was used to build a range of machine learning multiclassification models for
subgroup prediction. Due to a strong class imbalance in our 29 protein dataset (majority
of proteins belonging to Subgroup 18), SMOTE was applied to the dataset to oversample
minority classes. (Figure 24)

Figure 24. Synthetic data generation to correct class imbalance within the Class A GPCR dataset via SMOTE. Minority
classes were oversampled to reach an equivalent n to the Subgroup A18 class.
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The resulting dataset was randomly split 70% into a training set and 30% into a
test set for the building and testing of a range of machine learning models to predict an
output class reflective of Class A Subgroup. While multiple models were evaluated, only
the results for the top five highest performing models are shown: support vector machine,
K-nearest neighbors, bagged trees, random forest, and extra trees. Each model was
trained and tested on two separate feature sets—one containing the mean square
fluctuation data for each aligned residue position in the dataset, and a reduced feature set
only containing mean square fluctuations for the top 15% highest-variation residue
positions. These feature sets were contrasted for 10-fold cross validated F1-score
performance (Figure 25) and training time (Figure 26).

Figure 25. Reducing feature set by 85% via structural-based variance threshold does not significantly reduce crossvalidated F1-score based-accuracy of classifiers including support vector machine, K-nearest neighbors, bagging trees,
random forest and extra trees. (k=10)
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Figure 26. Reducing feature set by 85% via structural-based variance threshold significantly reduces training time of
classifiers including support vector machine, K-nearest neighbors, bagging trees, random forest and extra trees.
(k=10)

While we hypothesized that structure-based feature selection methods may
potentially increase model classification accuracy from an overall reduction in noise and
irrelevant data features introducing bias to the model, we did not see a significant
improvement in model performance following variance threshold feature reduction.
Model performance was not significantly affected by variance threshold structure-based
feature selection in a positive or negative direction for any tested models. We also
hypothesized that reducing the feature space via structure-based feature selection would
reduce training time for classification models and our results did support this hypothesis.
Average percent decrease in training time was significant for each model. Particularly for
higher complexity models, egregiously long training times are a major limiting factor for
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the real world application and feasibility of machine learning prediction. Although this
strategy did not improve model classification accuracy, a decrease in time-associated
computational cost without sacrificing accuracy is in itself an improvement in model
performance.
It is of interesting note that the random forest model on average had a relatively
modest reduction in training time but a slight increase in F1-score. While the increase in
accuracy was not significant for this experiment, it is potentially possible that a more indepth optimization of the random forest classifier may further increase this boost in
performance and exploratory analysis of the factors underlying this improvement other
than decreased training time may potentially result in useful guidance for future work.
Moreover, further analysis of the relationship between predictive model architecture and
efficacy of this feature selection strategy is warranted from a computer science
perspective, but beyond the scope of the biomedical objectives of this research.
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4.3

Specific Aim 3. To implement a novel deep neural network classifier

for the binary prediction of drug-binding activity for a dataset of (a) serotonin and
(b) dopamine Class A GPCRs.
4.3.1

Implementation of structure-based feature selection methods for deep

neural network classifiers
While data collected in Specific Aim 2 demonstrates the potential for structure-based
feature selection methods, the overall typical training time for the tested models is
relatively reasonable for most application scenarios as compared to the training time cost
of a neural network, which can span from hours to days. Additionally, the classification
task was comparatively simple to an interaction prediction between a drug-target
interaction pair—particular when dealing with numerous ligands per the same target
receptor, and vice versa, resulting in redundant data features between observations.
We hypothesized that the application of structure-based feature selection methods to
deep neural networks trained for the classification of Subgroup A17 drug-target
interactions will reduce the number of unnecessary features and as a result, reduce
training time as previously evidenced in simpler architectures. Following the construction
of a deep neural network classifier as described in 3.13, models were trained for 500
epochs on a dataset of 5-HT drug-target interactions containing data features describing
both the receptor and ligand molecular structure. In addition to the fully comprehensive
feature set containing feature information for all receptor residues, a receptor feature set
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reduced by 85% via variance threshold selection (as previously described in section 4.2)
was also used to train the classifier to compare the extent to which we can reduce the
computational cost of the model via structure-based feature selection without sacrificing
classification accuracy. For each training set, only the receptor features were reduced and
the same ligand feature set was used. Reduction of features by 85% (features describing
42 residues as compared to 282 residues) did not result in a significant reduction in
classification accuracy as measured by 10-fold cross validated F1-score or ROC AUC
score. (Figure 27) However, this feature reduction method did result in an 85% reduction
in training time for the classifier. (Figure 28)
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Figure 27. Deep neural network classifier prediction of serotonin receptor activity accuracy was not significantly
reduced when the receptor feature set is reduced by 85% as determined by a 10-fold cross validated F1-score or ROC
AUC score.

Figure 28. Training time for a deep neural network classifier of serotonin receptor activity was significantly reduced by
45% when the receptor feature set is reduced by 85%.
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4.3.2

Deep learning classification of 5-HT receptor drug-target activities

Figure 29 shows the accuracy of a deep fully-connected feedforward neural network
against a large dataset of serotonin receptor drug-target interactions following structurebased feature selection methods to predict a binary output of active/inactive per
interaction pair. Deep learning accuracy was contrasted to other commonly applied
machine learning algorithms on the same dataset. Classification accuracy measured via
10-fold cross validated F1-score and ROC AUC score was significantly improved (p <
0.01) in the deep neural network (F1-score = 0.78, AUC = 0.77) as compared to other
models. Random forest and support vector machine classifiers also performed well
(approximately 10% lower accuracy than the deep learning model) while logistic
regression and AdaBoost algorithms had little to no predictive ability for 5-HT receptor
interaction behavior. (Figure 29)
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Figure 29. Deep neural network classifier substantially outperformed other classifiers (F1 = 0.78, AUC = 0.768)
for prediction of serotonin receptor binding behavior, including logistic regression, random forest, support vector
machine, and Adaboost as measured by cross-validated F1-score and cross-validated ROC AUC. (k = 10)

109

4.3.3

Deep learning classification of DRD receptor drug-target activities

The same network architecture was trained on dopamine receptor drug-target
interactions following structure-based feature selection and demonstrated significant
performance superiority (p < 0.01; F1-score = 0.93, AUC = 0.941) compared to other
models, as well as outperforming model accuracy for serotonin receptor drug-target
interaction prediction.(Figure 30) An unexpected result of this experiment is that each
model, with the exception of the support vector machine classifier, performed better on
the dopamine receptor dataset than the serotonin receptor dataset.
Although the dopamine receptor dataset is comprised of the same ANM-generated
receptor features and RDKit-generated ligand features and used to build a classifier with
the same architecture as the 5-HT dataset and model, average cross-validated F1-scoring
was approximately fourteen percent higher for the DRD dataset even in spite of a
significantly smaller sample size. In future studies, it is worth investigating the reasoning
behind this discrepancy. We suggest that a possible explanation for these results lies in
the structural similarity of dopamine receptors as compared to serotonin receptors, which
are known to have more structural variation between isoforms. [225] Previous work from
other groups and our findings suggest that training a classifier on a group of proteins too
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dissimilar from one another increases the difficulty of the learning problem despite
allowing for a larger amount of training data. [226]

Figure 30. Deep neural network classifier substantially outperformed other classifiers (F1 = 0.93, AUC = 0.941) for
prediction of dopamine receptor binding behavior, including logistic regression, random forest, support vector machine,
and Adaboost as measured by cross-validated F1-score and cross-validated ROC AUC. (k = 10)

111

4.3.4

Discussion of machine learning classifier performance for drug-target

interaction activities of 5-HT and DRD receptors
Deep neural network performance supported the hypotheses that deep learning
strategies will outperform lower-complexity machine learning models due to the high
dimensionality of the data and complexity of the research problem and that structurebased feature selection methods will effectively improve the model performance of drugtarget interaction classifiers via significant reduction of model training time. While
feature selection is a less necessary step prior to model training with neural networks as
compared to other machine learning models, our data reflects what has previously been
demonstrated the literature for the utility of feature selection in improving computational
time and cost for neural network classifiers. [227]
One of the frequently stated benefits of machine learning within computational
biochemistry studies is the improved efficiency and handling of big data as compared to
molecular dynamics and quantum mechanics trajectories, which can take days to run
simulations of a timescale ranging from fs to μs even using parallel computing. [83], [97],
[138] However, if the required architecture is highly complex and requires a comparable
level of available structural data, the resulting difference in computational cost between
simulation trajectories and machine learning models may not be a substantial enough
improvement in practice to argue that a meaningful technical innovation has occurred. To
compete with state-of-the-art molecular dynamics and quantum mechanics simulation, we
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present the argument that a machine learning algorithm for structural biochemistry
applications must provide two benefits: a more efficient computational framework and a
relatively comparable degree of application interpretability. While molecular dynamics
and quantum mechanics methods are computationally expensive, the amount of detailed,
interaction-specific structural insight provided is substantially more rich than what is
currently available from machine learning strategies.
As an example, consider recent published molecular dynamics studies of fentanyl
binding to the μ-opioid GPCR, demonstrating theoretical binding association and
dissociation of fentanyl to the μ-opioid receptor binding site with detailed conformational
mechanism predictions and novel structural insight. [152] To run these simulations,
parallel computing with multiple GPU nodes were necessary to run nanosecond-scale
trajectories. Despite the intensive computational power required, molecular dynamics
simulation can provide valuable insight into the structure-function relationship of a drugtarget interaction.
Deep learning classifiers such as DeepAtom have similar time- and computationalassociated costs and require identical amounts of experimentally obtained structure data
describing the drug-target complex and each binding partner independently, which can be
scarce for the overwhelming majority of protein families. [19] Despite possessing the
most complex pipeline of all four architectures included in Specific Aim One’s
comparative experiment, their reported accuracy is not any higher than the other
classifiers and it performed significantly worse against the GPCR Subgroup A17 dataset
(p < 0.01) than the other classifiers. In reference to the applicability of the knowledge
learned by the classifier beyond inhibition constant prediction, the authors provide no
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examples and suggest future studies augmenting molecular dynamics simulation with
their model. In contrast, DeepConv offers examples of model explainability via
demonstrating binding site and class prediction via convolution results per residue.
However, as demonstrated by our work presented in Specific Aim Two and published
results from other groups, both the binding site recognition problem and the protein
classification problem are easily solved by simpler architectures. [30], [199], [228]
While the body of literature has clearly demonstrated the ability of deep learning
classifiers and other machine learning models for studying drug-target interactions [19]–
[22], [84], it appears that rather than demonstrating performance, justifying utility of
these models is the true gap in the literature. Whereas current available models seem to
focus on applying the recent state-of-the-art advances in deep learning from a computer
science perspective, we observe a relatively comparable performance and cost/benefit
trade off of classifiers in a wide range of neural network architectures and both sequence
and structure-based inputs. While it is of value to take inventory of which computational
methods can or cannot be applied to biomedical applications, it is ideal to develop
predictive frameworks with the most efficient and accessible architectures where
possible.
Perhaps a better objective is to prioritize improving general model applicability via
improved feature engineering techniques and improved runtime for computational
models. One of the biggest strengths of our proposed deep neural network model is the
relative ease of implementation and flexibility of input data formatting requirements.
Although numerous architecture types were tested in preliminary experiments (e.g.,
convolution on ANM data, recurrent backpropagation through time on sequence data;
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data not shown), increasing model complexity only marginally improved accuracy while
substantially increasing computational cost. As a result, we chose to proceed with a fully
connected feedforward network.
Additionally, the use of ANM for feature engineering in our pipeline finds balance
between sequence- and structure- based methodologies. While sequence based methods
limit performance and explainability, many structure based methods require high
computational cost or a volume of available data that is often unrealistic in real-world
scenarios (i.e., inactive apostructure and active bound structure for each individual drugtarget interaction). Normal mode analysis strategies such as ANM provides a compromise
– extracting meaningful, three-dimensional characteristics of a receptor’s structure
compressed into a one dimensional fingerprint and dynamic behavior without the
necessity of complex simulation trajectory. Solved structures for the drug-target complex
are not necessary and the receptor features can be generated separately from the ligand
features, therefore only the receptor structure is necessary. Because the model allows for
fluid range through multiple conformations, the current state or conformation of the
experimental structure is not a key factor. While the ANM calculations add model
complexity, it is comparatively simpler than many of the discussed alternatives and the
predictive classifier is quick to train.
In addition to model efficiency and broad application range due to easily-attainable
input data requirements, a key factor in the general applicability of this model is the ease
of implementation for a broad range of users. The model architecture is relatively easy to
set up with minimal machine learning experience, allowing biochemistry and
pharmacology researchers without extensive bioinformatics experience to utilize the tool.
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4.3.5

DRD drug-target interaction selectivity prediction for specific clinical

applications
Dopamine receptor selectivity majorly influences physiological effects and adverse
reactions of dopamine signaling modulating drugs. As an example, behavioral effects and
overdose risk from recreational stimulant compounds with differing DRD binding
activity display different risk profiles. [229] Benzomethyl ecgonine, or cocaine, is a
naturally occurring anesthetic often taken recreationally for its off-label physiological
effects including euphoria, increased energy, and lowered inhibition. [230] At higher
doses or chronic exposure, adverse effects include restlessness, aggression, hallucination,
decreased cardiovascular performance, weight loss, and respiratory damage when
administered nasally or inhaled. [39], [231] Unlike other stimulants such as
amphetamines, the molecular structure of cocaine does not resemble dopamine and is not
a known interacting partner for any GPCR including the dopamine receptors. [26], [206]
A tool that capable of predicting specific activity at the dopamine receptor for
dopamine reuptake inhibitor drugs is impactful to the clinical community. Although
cocaine does not increase dopamine production, release, or serve as a dopamine receptor
agonist, administration of cocaine still results in enhanced dopamine signaling activity
via inhibiting the reuptake of dopamine into the nerve terminal via interaction with
dopamine transporters, effectively increasing the concentration of cocaine in the synapse
available to interact with dopamine receptors. [230]
In contrast, certain ‘designer drug’ stimulants of the cathinone class such as
methylenedioxypyrovalerone (MDPV) (also referred to as ‘bath salts’) act simultaneously
as a dopamine reuptake inhibitor and a dopamine receptor agonist at the D3 receptor.
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[229] As a result, dopamine signaling is upregulated through both increased dopamine
concentrations in the synapse and agonism at the receptor, intensifying physiological
effects and toxicity risk. MDPV is associated with a higher level of adverse effects than
other stimulants including an increased anxiogenic effect, increased aggression, intense,
prolonged panic attacks, chronic psychosis symptoms, and higher risk of overdose. [229],
[231]
Other designer drugs (i.e., a term typically referring to novel alterations of well
known psychoactive compounds with enhanced pharmacological effects developed
outside of the realm of medical and legal jurisdiction) in the stimulant category display a
similar behavioral pattern of acting simultaneously as a dopamine reuptake inhibitor and
a dopamine receptor agonist. [26], [229] Collecting experimental evidence for the
relationship between the pharmacological activity profile of designer drugs and their
toxicological effects is beyond the scope of this work; however, we hypothesize that one
can reasonably infer that dopamine agonist activity in addition to dopamine reuptake
inhibitor activity changes the adverse effect profile of a drug.
Within the dataset of psychoactive compounds obtained from the PDSP database, we
identified dopamine receptor activity at the D3 receptor, but not the structurally similar
D2 or D4 receptors, for designer drugs including MDPV, PPP, methedrone, and PVT.
[26] The D2, D3, and D4 isoforms are sometimes grouped separately as their own
subtype due to their similar structural and functional characteristics (“Type 2 DRD
receptors”), while the D1 and D5 isoforms are considered a separate subtype for their
respective similarities (“Type 1 DRD receptors”). [206], [232] One could hypothesize
that our deep learning classifier is simply capable of identifying generalized relationships
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between the drug structure and its activity against type 1 or type 2 DRD receptors, but
due to their structural similarities, cannot differentiate between receptors within the same
subtype. To test this hypothesis, we collected a subset of our original DRD receptor
dataset for drugs that are selective to either the D2, D3, or D4 receptor (i.e., active at one
of the three Type 2 isoforms and inactive at the other two) for a total of 39 observations.
Interactions involving the Type 1 DRD receptors or nonselective drugs were omitted
from the dataset. Our Type 2 DRD receptor dataset was used as additional test set for the
pre-trained model on DRD receptor drug-target interactions. As done previously,
predicted output of the model is a binary value corresponding to the activity of the given
drug-target interaction pair. The performance metrics for this experiment are given in
Figure 31.

Figure 31. Accuracy of the deep neural network classifier on a test set of selective DRD drug-target interactions.
Precision = 1.0, recall = 0.7857, false positive rate = 0.0, false negative rate = 0.2143, classification accuracy = 0.9231.

Model accuracy is comparable to that of the previous DRD receptor test set,
disproving the hypothesis and providing evidence that the model is able to learn isoformspecific structure-function relationships for ligand binding rather than generalizing
patterns between isoforms with similar structure.
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To further test this hypothesis, we also chose to repeat this experiment with a dataset
containing only D2-selective or D4-selective compounds but further reducing the dataset
to remove D3-selective compounds resulting in a subset containing 20 observations. This
experiment was motivated by the clinical significance of D2 versus D4 receptor
selectivity in psychoactive drug behavior. Between 30-60% of patients taking D2
agonists such as antipsychotics report sexual adverse effects including erectile and
ejaculatory dysfunction, low libido, and priapism in men and low libido, orgasmic
dysfunction, and disturbances to fertility in women. [42], [55], [233]–[235]
In contrast, D4 agonists such as anti-parkinsonism and non-stimulant ADHD
therapeutics have a documented potential to increase libido, induce erections in men, and
improve vaginal lubrication and orgasm frequency in women. [236]–[238] While
currently available sexual function drugs such as Viagra and Cialis are within the PDE
inhibitor class, up to 40% of men with erectile dysfunction are non-responsive to PDE
inhibitor treatment. [236] Potential sexual dysfunction therapeutics including D4 agonists
have been documented in the literature as novel alternatives to PDE inhibition. [235],
[236]
Figure 32 summarizes the performance metrics of the deep learning classifier
when tested on ability to differentiate between D2-selective and D4-selective compounds.
Again, we see a high classification accuracy with this test set. By testing our model on
various combinations of receptors, we have demonstrated the model’s overall capacity for
predicting dopamine receptor drug-target activity as well as dopamine receptor-targeting
drug selectivity for highly clinically relevant applications.
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Figure 32. Accuracy of the deep neural network classifier on a test set of drug-target interactions selective for the D2 or
D4 receptor. Precision = 1.0, recall = 0.8, false positive rate = 0.0, false negative rate = 0.2, classification accuracy = 0.95.
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5. Conclusion and Future Work
In summary, we have demonstrated the utility of bioinformatic tools to analyze the
relationship between structure and function for protein receptors, providing valuable
insight into binding selectivity patterns. Specifically, we have demonstrated the efficacy
of these strategies for the Class A GPCRs, and in further detail for the Subgroup A17
GPCRs and the clinical impact of predictive tools for these drug-target interactions.
Within the last ten to fifteen years, machine learning models have grown in popularity
and promise for the classification of protein-ligand interactions, particularly within the
specific investigation of drug-target interaction activity. Recent work has yielded
numerous high-performing predictive models for drug-target interactions with some
degree of transferrable knowledge to psychoactive GPCR interactions, but improvement
is still necessary to improve the general applicability and feasibility of these models.
Specific Aim One demonstrates the weaknesses of the current top performing models for
protein-ligand interaction as well as raises a question about the value of input feature
quality versus model complexity when modeling protein-ligand binding activity. We
have presented a novel predictive pipeline combining computational tools from
established biochemical modeling techniques, chemical physics simulation, and deep
learning for an interdisciplinary framework focused on optimizing not only classification
accuracy for predicting drug-target interaction activities, but also model efficiency and
practicality.
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We have added further evidence to the growing body of literature demonstrating the
utility of normal mode analysis methods such as the anisotropic network model in
structure-based drug design methodologies. By combining structural analysis with
machine learning, we provide structure-function relationship insight that is both accurate
and interpretable for GPCR drug-target interactions. While multiple published models
have reported high accuracy scoring for protein-ligand interactions, it remains a challenge
to extract meaningful information about the conformational dynamics underlying binding
activity from machine learning models. While machine learning can provide fast and
relatively accurate predictions on the likelihood of a binding interaction to occur, overall,
molecular dynamics still remains the superior choice for model explainability. By
integrating ANM into our machine learning pipeline as a feature engineering strategy, we
sought to strike a balance between the computational efficiency of machine learning
prediction and the level of structural detail in molecular model simulations. Results from
Specific Aims Two and Three exhibit a range of visualizable structural examples for
Class A GPCR interactions relevant to the pharmacology of schizophrenia and mood
disorder therapeutics, dementia therapeutics, and substance use disorders.
We hypothesized that a deep learning classifier would be necessary to accurately
predict the activity of Subgroup A17 GPCR drug-target interactions due to the complex
nature and high dimensionality of the data. This hypothesis was supported for serotonin
receptor interactions but other machine learning models generally performed quite well
for dopamine receptor interactions. Of note, the support vector machine performed
substantially worse than any other models tested for dopamine receptor interaction
activity classification. It is possible that the receptor structures are too similar to be
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separated using a SVM kernel. In the future, further optimization and investigation is
necessary to elucidate the patterns in learning skill demonstrated by different models and
data sources in this work.
A significant challenge in completing these experiments lies in the substantial lack
of publicly available, reliable experimental data for drug-target interactions. While we
chose to use oversampling methods to generate synthetic data for non-real interactions,
there are predictive modeling methods available to predict three-dimensional structure for
proteins based on sequence, homology, or a combination of both. The validity of these
theoretical models is still strongly contested, therefore we chose to only include
experimentally validated structures in our dataset. However, it may be possible to include
these protein structure predictions in datasets to make predictions for receptors that do
not have an experimentally obtained structure. In future directions, it would be of great
benefit to determine the effect of training a drug-target interaction classifier with these
predicted structures. If performance can be maintained, this experiment would
simultaneously present evidence for the validity of computationally generated protein
structures and widely increase the range of applicability for interaction classifiers.
In conclusion, we hypothesized that Class A GPCR binding activities can be more
efficiently predicted via combining feature engineering and selection based on
physiochemical models and deep learning models with subgroup-specific training. In
Aim One, we were unable to replicate model performance for pre-trained deep learning
classifiers from the literature when tested on a dataset of Subgroup A17 receptor
activities. This data provides supporting evidence for our hypothesis suggesting that
models trained on a broad protein dataset may not generalize as well to specific protein
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subgroups as compared to models trained on datasets containing same-subtype proteins
as test data, despite a potentially smaller training set size. Aim Two data demonstrates
that the use of feature selection guided by structure can significantly reduce the training
time of machine learning models for protein receptor classification problems. Moreover,
in Aim Three, we show that this feature selection strategy results in agile training of deep
learning classifiers for drug-target interaction activity for two datasets of Class A17
GPCR interactions corresponding to serotonin and dopamine receptors, respectively. The
deep learning models generated maintained comparable-or-higher classification accuracy
to previously published methods (F1-scores and AUC scores ≥ 0.78) with significantly
reduced training time (45% reduction as compared to model architecture trained without
feature selection). Cumulatively, this evidence supports the original hypothesis that our
proposed framework is capable of maintaining accuracy while improving efficiency of
deep learning classifiers for prediction of Subgroup A17 GPCR drug-target interaction
activities.
This work establishes a meaningful contribution to the field of bioinformatics within
structure-based drug design. Our novel feature engineering and selection methodology
based on the unique conformational behavior of a given structure allows for in-depth
structural input features without leading to training time exceeding what is feasible for
real-world application. Our deep learning architecture is capable of providing an
improvement to model accuracy while simultaneously scaling down model complexity to
increase the range of applicability and decrease learning curve difficulty for new users.
Within the realm of psychoactive research, low selectivity of therapeutic compounds
and unacceptably high rates of toxicity and adverse effects have been a high priority area
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of pharmacology research following an overwhelmingly large body of literature
suggesting an unacceptable level of risk associated with a range of psychiatric
medications that has resulted in a sharp decrease in the number of GPCR-targeting
psychoactive compounds receiving FDA approval over the last decade. [18], [75], [80],
[239]–[241] Despite this project focusing specifically on GPCR interaction activity
within the psychiatric lens, the gained perspective and valuable strategies developed here
are highly translatable to any application of protein structure/function relationship
analysis. This project serves as a strong foundation for future structure-based drug design
and structural analyses across a broad range of clinical applications.
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Appendix A. Receptor and Drug Features
A.1 Receptor feature engineering from ANM output
Receptor features each correspond to a given residue in which residue numbering
corresponds to the multiple structural alignment for the given dataset. Following
calculation of atomic fluctuations as described in 3.4, each protein is encoded by a feature
vector in which index corresponds to residue number and elements correspond to mean
atomic fluctuations for the alpha carbon of the given residue position for use in machine
learning classifiers. An example representation of input data format is given in Table
A1.1. All ANM output can be found in a Bioinformatics Research Group Github
Repository.
…

AlignedRes_n

Cα_fluct_2GPCR_1 Cα_fluct_3GPCR_1

…

Cα_fluct_nGPCR_1

Cα_fluct_1GPCR_2

Cα_fluct_2GPCR_2 Cα_fluct_3GPCR_2

…

Cα_fluct_nGPCR_2

GPCR_3

Cα_fluct_1GPCR_3

Cα_fluct_2GPCR_3 Cα_fluct_3GPCR_3

…

Cα_fluct_nGPCR_3

…

…

…

…

…

GPCR_n

Cα_fluct_1GPCR_n

Cα_fluct_2GPCR_n Cα_fluct_3GPCR_n

…

Cα_fluct_nGPCR_n

AlignedRes_1

AlignedRes_2

GPCR_1

Cα_fluct_1GPCR_1

GPCR_2

AlignedRes_3

…

Table A1.1 Format of data features for protein receptors. Each protein corresponds to a data observation in which
each feature describes the mean atomic fluctuations for each aligned residue as determined by an anisotropic network
model.

155

A.2 Drug feature encoding
Chemical features were generated from SMILES using the RDKit Chem.Features
package in Python 3.6. [209] Features belong to the following molecular descriptor
categories:
Gasteiger/Marsili Partial Charges

BalabanJ

BertzCT

Ipc

HallKierAlpha Kappa1-Kappa3

Phi

Chi0,Chi1

Chi0n-Chi4n

Chi0v

Chi4v

MolLogP

MolMR

MolWt

ExactMolWt

ExactMolWt

HeavyAtomC

HeavyAtomMolWt

ount
NHOHCount

NOCount

NumHAcceptors

NumHDonors

NumHeteroato NumRotatableBonds
ms

NumValenceElectrons

Num{Aromatic,Saturated,Aliphatic}{

NumAmideBo

Num{Aromatic,Saturated,

nds

Aliphatic}Rings

RingCount

FractionCSP3

NumBridgehe

TPSA

Hetero,Carbo}Cycles
NumSpiroAtoms

adAtoms
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LabuteASA

PEOE_VSA1

SMR_VSA1-

–

SMR_VSA10

PEOE_VSA14
SlogP_VSA1 – SlogP_VSA12

Estate_VSA1-

VSA_Estate1 –

Estate_VSA11 VSA_Estate10
MQNs

Topliss

Autocorr2D

Fragments
BCUT2D

Eccentricity

SSSR

Table A2.1 Molecular descriptors selected from the RDKit package to be used as features in machine learning
prediction. Expanded list with notes for each descriptor calculation as well as code can be found in the RDKit
documentation. [209]
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Appendix B. Code Source and Examples
B.1. Dataset generation and cleaning
To obtain comprehensive datasets of GPCR interaction activities, all datasets (GPCRdb
for receptor and receptor structure data [23], PDSP for psychoactive drug activities [26],
and DrugBank [207] for ligand structure data) were imported into SQLite [242] for
database management and combined using the relational algebra join functions in SQLite
to obtain a database containing only activities for interactions between GPCRs and
psychoactive drugs in which the GPCR has an experimentally solved structure and the
ligand SMILES can be obtained. Protocol and code for using SQLite join functions can
be found in the SQLite documentation. [242]
Following the generation of the GPCR/psychoactive drug database, data cleaning was
performed in OpenRefine to remove any duplicate observations or observations
containing missing values, encode activities into a binary output, and remove interactions
with multiple entries that are not in agreement as previously described in 3.2. OpenRefine
source code can be obtained at openrefine.github.com.
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B.2. Data loaders
All data loaders use the Dataset and DataLoader module within PyTorch. [243]
## train data
class trainData(Dataset):
def __init__(self, X_data, y_data):
self.X_data = X_data
self.y_data = y_data
def __getitem__(self, index):
return self.X_data[index], self.y_data[index]
def __len__ (self):
return len(self.X_data)
train_data = trainData(torch.FloatTensor(X_train),
torch.FloatTensor(y_train))
## test data
class testData(Dataset):
def __init__(self, X_data):
self.X_data = X_data
def __getitem__(self, index):
return self.X_data[index]
def __len__ (self):
return len(self.X_data)
test_data = testData(torch.FloatTensor(X_test))

train_loader = DataLoader(dataset=train_data, batch_size=BATCH_SIZE,␣
,!

shuffle=True)

test_loader = DataLoader(dataset=test_data, batch_size=1)
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B.3. Deep learning classifier
Deep neural network architecture was built using the torch.nn module within PyTorch.
[243]
class binaryClassification(nn.Module):
def __init__(self):
super(binaryClassification, self).__init__().
self.layer_1 = nn.Linear(numFeat, 1400)
self.layer_2 = nn.Linear(1400, 1400)
self.layer_3 = nn.Linear(1400, 700)
self.layer_4 = nn.Linear(700,350)
self.layer_out = nn.Linear(350, 1)
self.relu = nn.ReLU()
self.dropout = nn.Dropout(p=0.1)
self.batchnorm1 = nn.BatchNorm1d(1400)
self.batchnorm2 = nn.BatchNorm1d(1400)
self.batchnorm3 = nn.BatchNorm1d(700)
self.batchnorm4 = nn.BatchNorm1d(350)
self.dropout2 = nn.Dropout(p=0.8)
def forward(self, inputs):
x = self.relu(self.layer_1(inputs))
x = self.batchnorm1(x)
x = self.relu(self.layer_2(x))
x = self.dropout(x)
x = self.batchnorm2(x)
x = self.relu(self.layer_3(x))
x = self.batchnorm3(x)
x = self.dropout2(x)
x = self.relu(self.layer_4(x))
x = self.batchnorm4(x)
x = self.dropout2(x)
x = self.layer_out(x)
return x
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B.4. Other machine learning models
All machine learning classifiers other than the deep neural network classifier were
built using scikit-learn. Protocols and code for each classifier can be found in the scikitlearn documentation at scikit-learn.org. [115]

All models were replicated from available GitHub repositories, referenced in each
respective publication. [19]–[22]
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B.5. Anisotropic network model
Anisotropic Network Models were built following the protocol created by the
Computational and Systems Biology research group at the University of Pittsburgh.
MATLAB [208] was used for all matrix manipulation and theoretical B-factor calculation
based on all normal modes using the eig function. C code for ANM calculations was
obtained from the ANM documentation from the Computational and Systems Biology
research group at the University of Pittsburgh at
http://anm.csb.pitt.edu/anmdocs/source.html. [184], [185], [244]
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B.6. Protein structure modeling and analysis
All protein structure models, simulation including solvation and minimization,
and intermolecular/intramolecular bond prediction were performed in UCSF ChimeraX.
Protocol and code can be found through the UCSF Chimera documentation at
https://www.cgl.ucsf.edu/chimerax/docs/user/index.html. [213]
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